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SaP234 THE ASSOCIATION OF CIRCULATING CARDIAC
BIOMARKERS WITH THE FREQUENCY AND SEVERITY
OF LEFT VENTRICULAR REGIONAL WALL MOTION
ABNORMALITIES
James Burton 1, Shvan Korsheed 1, Christopher McIntyre 1,2. 1Department
of Renal Medicine, Derby City General Hospital, Derby, United Kingdom;
2Centre for Integrated Systems Biology & Medicine, University of
Nottingham, Nottingham, United Kingdom
Introduction and Aims: Haemodialysis (HD) patients who develop my-
ocardial dysfunction have a poor prognosis. Recurrent sub clinical myocar-
dial ischaemia is an important risk factor in the development of heart failure
in non dialysis patients. We have previously demonstrated that sub clinical
myocardial ischaemia develops during HD. HD patients prone to episodes
of intradialytic hypotension (IDH) have higher levels of circulating cardiac
troponin T (cTnT) than non IDH-prone dialysis patients. HD patients with
an elevated cTnT also have an increased incidence of mortality from all
causes. We sought to examine whether increased cTnT levels were associ-
ated with the development, frequency and severity of left ventricular (LV)
regional wall motion abnormalities (RWMAs).
Methods: We studied 38 prevalent HD patients and took blood samples
for cTnT immediately prior to (baseline), immediately after the end of
(post) and 48hours after HD treatment. At the same treatment session, serial
echocardiography with quantitative analysis was performed pre-dialysis, at
peak stress and during recovery. This was used to assess the development
of wall motion abnormalities over 10 regions of the left ventricle. A motion
abnormality was defined as a reduction in movement of >20% from baseline
and >2 RWMAs were significant. Severity was scored as a composite of
the number of RWMA and the magnitude of reduction in motion.
Results: Circulating plasma cTnT levels did not correlate with left ven-
tricular mass index (LVMI) (P=0.37). Increased LVMI was not associated
with the development of RWMAs (P=0.25). Patients who developed RW-
MAs during HD had a higher baseline cTnT (0.028±0.006 vs. 0.1±0.017,
P=0.017). However, there was no correlation between levels of cTnT and
the severity of stunning as evidenced by numbers of RWMAs (P=0.3) or
the magnitude of reduction (P=0.31). There was also no significant rise in
the post (P=0.49) and 48 hour (P=0.48) cTnT levels from baseline in those
patients who developed left ventricular RWMAs.
Conclusions: The development of left ventricular RWMAs is associated
with an elevated cTnT. However, plasma cTnT levels do not forecast the
number of RWMAs that develop or their severity. Circulating biomarkers of
myocardial injury may be of use to identify patients experiencing dialysis
induced myocardial stunning. However, the degree of elevation appears to
correlate poorly with the severity of the functional insult.
SaP235 A NOVEL HIGHLY EFFICIENT BIO-ASSAY TO MONITOR
MICROBIOLOGICAL PURITY OF DIALYSIS FLUIDS
Griet Glorieux 1, Eva Schepers 1, Ralf Schindler 2, Francis Verbeke 1,
Norbert Lameire 1, Raymond Vanholder 1. 1Internal Medicine, Renal
Division, University Hospital Gent, Gent, Belgium; 2Nephrology and
Intensive Care Medicine, Charité-Virchow-Klinikum, Humboldt Universität
zu Berlin, Berlin, Germany
Introduction and Aims: Microbial contaminantion of the dialysis fluid
has a pro-inflammatory potential. The increased application of high-flux
hemodialysis and on-line hemodiafiltration has made the need for ultrapure
dialysis water even more stringent. Classical test methods for bacteriological
contamination, such as bacteriological cultures or the Limulus Amebocyte
Lysate (LAL)-test, fail to detect a substantial number of contaminants with
intact lipopolysaccharide (LPS) as the only exception.
Methods: We developed a novel bio-assay for dialysis water contaminants
using a monocytic THP-1 cell line. After a 24h rest period, calcitriol
(10nM)-differentiated (72h) THP-1 cells, were incubated overnight (24h),
in the presence of dialysis fluid samples (1/1) or samples containing potential
activating microbiological agents. Secretion of IL-1β (pg/ml) was detected
in the cell culture supernatant as a parameter of biological activity of the
dialysis fluid. To validate the sensitivity of this test method to various types
of contaminants, response to peptidoglycan (PGN), short bacterial DNA
fragments and LPS fragments was compared to the response observed with
the LAL-test.
Results: The presence of peptidoglycan (0.1; 1; 5; 10; 50; 100; 500;
1000; 5000 ng/ml) induced IL-1β secretion from 5 ng/ml on (P<0.05)
whereas the classical LAL-test remained unresponsive. Likewise, addition
of short bacterial DNA fragments (2006 stimu; 1μM and K3; 10μM)
caused a significant IL-1β induction but no LAL-response. LPS fragments
(MW<5kD) from P. aeruginosa induced no LAL-response, per se, but
showed a marked biological activity. Intact LPS induced a significant IL-1β
secretion versus control in a dose dependent manner from a concentration
of 0.01 ng/ml on. A comparable evaluation with a biological test based on
whole blood emanated in more scattered and/or less sensitive results.
Conclusions: The present data show that this novel bio-assay detects
bacteriological derivatives which cannot be found by the classical screening
methods. Application of this assay is useful to reveal contaminants which
otherwise go undetected aiming at the timely prevention of biofilm formation
in the dialysis circuit and micro-inflammation in the hemodialysis patient.
SaP236 ASSOCIATION BETWEEN TUMOR NECROSIS FACTOR
ALPHA (TNF) GENE POLYMORPHISM AND
CARDIOVASCULAR MORTALITY IN END-STAGE RENAL
DISEASE PATIENTS
Sawako Kato 1,2, Jonas Axelsson 1, Abdul Rashid Qureshi 1,
Yukio Yusawa 2, Yukio Maruyama 1, Peter Barany 1, Olof Heimburger 1,
Martin Schalling 1, Peter Stenvinkel 1 , Bengt Lindholm 1,
Louise Nordfors 1. 1Div. of Renal Medicine & Baxter Novum, Karolinska
Institutet, Stockholm, Sweden; 2Dept. of Internal Medicine, Nagoya
University Graduate School of Medicine, Nagoya, Japan
Introduction and Aims: Whereas circulating levels of pro-inflammatory
cytokines such as IL-6 are known to be closely associated with protein-
energy wasting, cardiovascular disease (CVD) and premature mortality in
ESRD patients (pts), such associations are not usually found with circulating
TNF, which could be due to the more local nature and shorter half-life of this
cytokine and many other factors. The TNF -308G/A gene polymorphism has
been reported to be associated with increased production of TNF. However,
the impact of this genetic polymorphism on CVD risk factors including
body composition, and mortality has not previously been studied in ESRD
pts.
Methods: A total of 229 ESRD (87 women, 5412 years) pts starting dialysis
therapy were genotyped for the TNF -308G/A gene polymorphism, and
relations with CVD mortality, body composition, inflammatory markers
including adipocytokines and various risk factors for CVD were analyzed.
Pts were followed for a median of 57 months (range 1-130 months).
Results: Sixty (26%) pts had the TNF -308G/A A allele. The circulating
levels of TNF and other cytokines did not differ from the levels in non-A
carriers. When analyzing the TNF genotype groups, systolic blood pressure
was however higher in the A allele carriers compared with non-A carriers
(p=0.049) and the body fat mass/body weight ratio was lower in the A allele
carriers (P=0.046) compared with the others. Furthermore, TNF -308G/A
A-carriers had higher levels of troponin T (cTnT) (p=0.01) and also showed
a higher CVD mortality during follow-up (Kaplan-Meier; Log-rank 6.38,
p=0.012). After adjustment for age, DM and inflammation (CRP>10mg/L),
wasting and presence of clinical CVD, the A allele of TNF -308G/A was
still significantly associated with a higher CVD mortality.
Conclusions: ESRD pts with the A allele of -308TNF, which is thought to
result in an increased transcription of TNF, was associated with hypertension,
lower fat body mass/weight ratio and higher serum cTnT levels as well
as with a significantly increased risk of cardiovascular death following
initiation of dialysis.
vi312 Cardiovascular complications of CKD 2 Saturday, June 23, 2007
SaP237 PERSISTENT ELEVATION OF INFLAMMATION MARKER
C-REACTIVE PROTEIN IS ASSOCIATED WITH
ATHEROSCLEROSIS AND LEFT VENTRICULAR
HYPERTROPHY IN CHRONIC HEMODIALYSIS PATIENTS:
2 YEAR FOLLOW-UP STUDY
Rahmi Yilmaz 1, Alper Kirkpantur 1 , Ali Deniz 2, Orcun Ciftci 2,
Bulent Altun 1, Mustafa Arici 1, Yunus Erdem 1, Unal Yasavul 1,
Cetin Turgan 1. 1Nephrology, Medical Faculty of Hacettepe University,
Ankara, Turkey; 2Cardiology, Medical Faculty of Hacettepe University,
Ankara, Turkey
Introduction and Aims: Cardiovascular disease is the main cause of
mortality in hemodialysis patients. The precise cause of this accelerated
mortality is still unclear. Recently, emerging evidence suggests that beside
the traditional risk factors, inflammation may have a role in the development
of cardiovascular disease. In addition, left ventricular hypertrophy (LVH)
and carotid intima media thickness (CIMT) was described as independent
risk factors for cardiovascular morbidity and mortality in this population
too. The aim of this study is to evaluate relation between inflammation
and CIMT and LVMI in patients with end stage renal disease undergo
hemodialysis.
Methods: Seventy-four HD patients without diabetes and history of cardio-
vascular disease were recruited in the two-years study. Forty-five patients
(20 female, 25 male, mean age; 52.6±14.1 years; mean time on HD 52±44
months) completed the study. CIMT and LVMI were determined baseline,
end of first and second years. Changing in CIMT and LVMI were calcu-
lated from these measurements at end of two year (CIMT and LVMI).
Biochemical parameters (creatinin, BUN, glucose, electrolytes, albumin,
hemoglobulin, lipid levels) were measured at the beginning of the study and
at four-week intervals; inflammatory markers (homocysteine, fibrinogen, C
reactive protein (CRP), erythrocyte sedimentation rate (ESR), lipoprotein-a)
and iPTH were determined at the initiation and at three-month intervals
during two-years. Mean values of biochemical parameters were calculated
yearly for each patient. Patients were stratified into two groups according
to mean serum CRP levels: low levels (<1 mg/dL; group I = 26 patients),
high levels (>1 mg/dL; group II = 19 patients).
Results: No difference was observed in traditional risk factors and mea-
surements of CIMT and LVMI between groups at the beginning of study. In
group-II, the mean value for CIMT and LVMI (0,67±0,15 mm; 91,6±34,2
g/m2, respectively) were significantly lower than measurements at two-
years (0,78±0,21 mm; 110.9±37,5 g/m2, respectively p<0,05). In group-I
patients had similar values of CIMT and LVMI at the beginning and end
of two years (0,65±0,15 vs. 0,68±0,17 mm/93,5±24,4 vs. 99,0±35 g/m2
respectively p>0,05). Incidence of patients with progressed CIMT and
LVMI was higher in patients’ group-II than in patients’ group-I (n=16, 85%
vs. n=3, 23% respectively, p<0,05). During two-years, systolic and diastolic
blood pressure, Kt/V, interdialytic weight gain, hemoglobin levels, CRP,
ESR, lipoprotein-a and lipid levels did not show significant variation and
difference between groups.
Conclusions: Our study showed inflammatory state of hemodialysis patients
might have an impact on the CIMT and LVMI progression thereby
cardiovascular disease in this population. CRP, the prototype marker of
inflammation may be also important prognostic indicator for atherosclerosis
and left ventricular dysfunction in patients with ESRD.
SaP238 A COMPARISON OF THREE DIFFERENT THERAPEUTIC
OPTIONS IN PREVENTION OF INTRADIALYTIC
HYPOTENSION
Ljubisa Veljancic, Rajko Hrvacevic, Milorad Radojevic, Zoran Kovacevic.
Department of Haemodialysis, Clinic of Nephrology VMA, Belgrade,
Banjica, Serbia
Introduction and Aims: In spite of all hemodialysis technology advances
and despite of all pharmacological and other preventive interventions,
intradialytic hypotension (IDH) remains very frequent complication of
hemodialysis (HD) treatment. Most authors report the presence of IDH in
15-30% of all HD treatments. Among technical devices, most promising is
ultrafiltration (UF) control by Blood Volume Monitor (BVM) along with
zero temperature balance by BTM-Blood Temperature Monitor. (BVM and
BTM are trade marks of Fresenius, Bad Homburg, Germany). Among
medications, positive effects are reported with administration of midodrine
(alpha-1 adrenergic receptor agonist) or sertraline (serotonin reuptake
inhibitor). Those three therapeutic options have not been compared directly
in the same group of patients. The aim of this paper was to show our results
of comparison of the efficacy of each that protective-therapeutic maneuver
in the prevention of IDH.
Methods: Ten (6 female, 4 male) chronic (7,3±4,5 years) HD patients
(mean age 59,0±20,5 years; range: 28-82) which were prone to IDH
(IDH in more than 40% of HD treatments), after first (monitoring) phase (9
standard HD treatments, during 3 weeks) underwent three therapeutic phases
in random order in a blinded fashion: B-phase (biofeedback, controlled UF
rate by BVM, with zero temperature balance achieved by BVM), M-phase
(midodrine, 10 mg per os, 30 min. prior to HD, during 3 weeks), S-phase
(sertraline, 50 mg p.o. daily, during 3 weeks). In every phase, for each
patient, blood pressure and pulse were measured in the same time periods
of HD, and the number of episodes of IDH was noted.
During the study, all patients had their usual dialysis conditions, and they
were asked not to change significantly their usual interdialysis weight gain,
medications and life habits.
Results: In the first phase, during 3 weeks and 90 HD treatments, 80 IDH
episodes were registered, or 0,89±0,23 episodes per treatment. Individual
critical Relative Blood Volume (crit.RBV) was determined for each patient.
Mean value of all crit.RBV was 81,1±3,9% (range 74-87%). In the second
part of the study, during B-phase: 27 IDH episodes (0,30±0,25 episodes
IDH per treatment), during M-phase: 57 IDH episodes (0,64±0,23 episodes
IDH per treatment), and in S-phase: 63 IDH episodes (0,70±0,25 episodes
IDH per treatment).
Conclusions: According to the obtained results, we concluded that all
three therapeutic options significantly decrease the number of IDH episodes
compared to the first or monitoring phase (p<0,01). “Biofeedback” (with
BVM and BTM) control of HD was more efficient way to prevent IDH than
both other (midodrine or sertraline) options (p<0,01), and there were no
significant difference between last two therapeutic options (p>0,05).
SaP239 PUROMYCIN AMINONUCLEOSIDE-INDUCED
NEPHROTIC SYNDROME PRESENTS CARDIAC
ATROPHY, CONTRACTILE DYSFUNCTION AND
CYTOKINE ACTIVATION
M. Moreira-Rodrigues 1, R. Roncon-Albuquerque Jr 2,
T. Henriques-Coelho 2, A.P. Lourenço 2, B. Sampaio-Maia 1, J. Santos 1,
A.F. Leite-Moreira 2, M. Pestana 1. 1Unit of Research and Development of
Nephrology, Faculty of Medicine, Porto, Portugal; 2Department of
Physiology, Faculty of Medicine, Porto, Portugal
Introduction and Aims: In the nephrotic syndrome (NS), the impact
of protein wasting and inflammatory activation on cardiac remodeling
is still unknown. In the present study, cardiac morphometry, contractile
function and myocardial gene expression were evaluated in puromycin
aminonucleoside (PAN)-induced nephrosis.
Methods: Male Sprague-Dawley rats were studied 7 and 14 days after
PAN (150 mg.kg-1; ip) injection. Cardiac and skeletal muscle morphometry
and protein concentration to DNA concentration ratio were evaluated.
Renal function, blood pressure, cardiac hemodynamics and muscle strip
contractile function were assessed. Evaluation of myocardial expression of
cytokines, growth factors, calcium-handling and myofilament proteins was
also performed. Statistical analysis was performed by one-way ANOVA
followed by Student’s t-test for unpaired comparisons.
Results: PAN injection consistently resulted in massive proteinuria and
impaired creatinine clearance. Sodium retention was observed at day 7,
while a negative sodium balance was present at day 14 with no changes
in blood pressure or end-diastolic pressures. Skeletal and cardiac muscle
atrophy were present in PAN treated animals 14 days after injection. This
was accompanied by disturbed left ventricular (LV) systolic and diastolic
function, and impaired performance of LV isolated muscle strips. Increased
LV mRNA levels of cytokines TNF-α and IL-1b and decreased mRNA
and protein expression of SERCA2a were also observed. This resulted in a
reduction of SERCA2a to PLB ratio in the PAN group on day 14.
Conclusions: PAN nephrosis associates with cardiac atrophy in the absence
of altered loading conditions. This resulted in myocardial dysfunction in the
presence of local cytokine activation and disturbed calcium-handling mRNA
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and protein expression. These results suggest that, in the NS, systemic
inflammatory activation and protein wasting induce cardiac remodeling and
dysfunction.
*Supported by Grants POCI/SAU-OBS/55288/2004 from Fundação para a
Ciência e a Tecnologia - FEDER and Grant by Sociedade Portuguesa de
Nefrologia.
SaP240 ASSOCIATIONS OF SIALIC ACID WITH INDICES OF
MALNUTRITION-INFLAMMATION AND
ATHEROSCLEROSIS IN HEMODIALYSIS PATIENTS
Paraskevi Tseke 1, Eirini Grapsa 1, Elisabeth Samouilidou 2 ,
Paraskevi Voidonikola 3 , Paraskevi Katsihti 3, Anna Vourliotou 4 ,
George Rammos 5, Antonios Laggouranis 1. 1Nephrology, General Hospital
“Alexandra”, Athens, Greece; 2Biochemical Laboratory, General Hospital
“Alexandra”, Athens, Greece; 3Vascular Laboratory, General Hospital
“Alexandra”, Athens, Greece; 4Renal Unit, Errikos Dynan Hospital,
Athens, Greece; 5Clinical Therapeutics, University of Athens, General
Hospital “Alexandra”, Athens, Greece
Introduction and Aims: Sialic acid (SA) is a derivative of neuraminic acid,
which is expressed on lipoproteins, glycolipids and acute phase reactants.
SA has been shown to be a risk factor for cardiovascular (CV) morbidity and
mortality in general population and in diabetics. It has been also shown to be
elevated in patients with end stage renal disease, especially in those with CV
disease. However, SA has not been evaluated as marker of atherosclerosis in
non-diabetic, asymptomatic patients on chronic maintenance hemodialysis
(MHD).
Aim of our study was to evaluate sialic acid as a marker of atherosclerosis
in asymptomatic, non-diabetic chronic MHD patients.
Methods: Seventy stable, non-diabetic asymptomatic patients on chronic
MHD (40 females and 30 males) and 30 healthy controls (15 females and
15 males) were examined for the presence of atherosclerosis with B-mode
carotid ultrasound, estimating intima-media-wall thickness (IMT) bilaterally.
All participants underwent clinical evaluation including assessment of
antropometric indices and biochemical blood tests including high-sensitivity
CRP and plasma fibrinogen, total SA and lipids.
Results: SA was significantly increased in MHD patients compared to
controls in age-sex adjusted model (OR: 1.03, p=0.018). In univariate
linear regression analysis SA correlated positively with CRP (r=0.79,
p<0.0001), fibrinogen (r=0.44, p<0.0001), triglycerides (r=0.26, p=0.02)
and carotid IMT (r=0.26, p=0.04) and negatively with serum albumin
(r=-0.27,p=0.02) and predialysis serum creatinine (r=-0.37, p=0.001) in
MHD patients. In stepwise multivariate regression analysis for carotid IMT
SA (beta:0.0012, p=0.02), age (beta:0.004, p=0.012) and waist-to-hip ratio
(beta:0.57, p=0.026) were found to be independent predictors of carotid
IMT in non-diabetic MHD patients.
Conclusions: Serum SA is elevated in non-diabetic MHD patients and it
seems to be strongly associated with established markers of CV disease
(CRP, IMT). There is evidence that SA could be a marker of MIA syndrome
in such patients, since it is seems to be associated with malnutrition
(lower serum albumin and creatinine), chronic systemic inflammation (CRP,
fibrinogen) and atherosclerosis (IMT) in chronic MHD patients. However,
further clinical research is necessary to confirm this finding.
SaP241 LIPID PROFILE AND CARDIOVASCULAR RISK IN
DIALYSIS: TWO-YEARS FOLLOW UP FROM RISCAVID
STUDY
Giovanni Grazi, Giovanni Manca Rizza, Vincenzo Panichi,
Sabrina Paoletti, Valentina Marchetti, Emanuela Mantuano, Sara Beati,
Stefano De Pietro, Roberto Menicucci, Valentina Batini, Erica Panicucci,
Brunella Andreini, Giancarlo Betti, Roberto Palla. RISCAVID Study Group,
North-West Tuscany, Italy
Introduction and Aims: Atherosclerotic cardiovascular (CV) disease is the
first cause of mortality and morbility in uremic patients and both altered
lipidic profile and chronic inflammatory state play an important role in its
pathogenesis. The RISCAVID (Cardiovascular risk in Dialysis) study is an
observational and prospective study, started on June 2004, of the over 800
patients in hemodialysis (HD) and peritoneal dialysis of the north-western
area of Tuscany. Aim of this study is to verify the predictive power of
various risk factors regarding CV events in HD patients.
Methods: At the time of enrolment basal demographic, clinical and
laboratory data of population were registered (n=757, m 60%, mean
age 65.6±14 y, dialytic age 69±77 m, diabetes 19%). CV disease was
established by anamnestic and instrumental data. Serum cholesterol (sC),
serum tryglicerid (sTg) and HDL cholesterol (HDL-C) were directly
measured (Beckman); LDL cholesterol (LDL-C) was indirectly calculated
by Friedewald’s formula. Chronic inflammatory state was evaluated by
centralized dosage of CRP (highly sensitive nephelometric assay, Bering),
IL-6 and IL-8 (EIA, Bender). The population was followed up for 24 months
reporting CV major events (acute myocardial infarction, stroke and ictus),
CV mortality and overall mortality.
Results: Patients with LDL-C >70 mg/dl (65% of the entire population)
were associated with a significantly increased risk of CV mortality (RR 1.35,
p<0.04,). HDL-C >40 mg/dl was showed protective on fatal and non fatal
CV events. Patients with HDL-C<40 mg/dl and LDL-C > 70 mg/dl were
associated with an higher cumulative RR for non fatal CV events (1,42; p<
0.05) and CV mortality (1,61; p<0.01). No predictive power was founded
for total cholesterol and trygliceride values. Patients with pro-atherogenic
lipidic profile (LDL-C>70 mg/dl) and inflammatory state (CRP>5 mg/L)
showed an increased RR of mortality and morbility in respect to patients
with only one risk factor. Nevertheless, patients with low LDL-C (< 70
mg/dl) shower an increased RR for overall mortality (RR 1,22; p<0.05).
Conclusions: RISCAVID Study after a two-year follow-up confirms the
importance of proatherogenic lipidic profile in the HD population. The
combination of high levels of LDL-C, low levels of HDL-C and increased
pro-inflammatory cytokines improves prognostic value of analysis for CV.
Low levels of LDL-C are associated with an increased risk for overall
mortality supporting the concept of “reverse epidemiology”.
SaP242 PULMONARY HYPERTENSION IN END STAGE RENAL
DISEASE PATIENTS: PREVALANCE AND RISK FACTORS
D. Deren Oygar 1, Umut Hakligil 2 , Guzin Zekican 3, Dilaver Akdur 4,
Gulgun G. Vaiz 3. 1Nephrology, Lefkosa Burhan Nalbantoglu Devlet
Hastanesi, Nicosia, Cyprus; 2Internal Medicine, Lefkosa Burhan
Nalbantoglu Devlet Hastanesi, Nicosia, Cyprus; 3Cardiology, Lefkosa
Burhan Nalbantoglu Devlet Hastanesi, Nicosia, Cyprus; 4Radiology,
Lefkosa Burhan Nalbantoglu Devlet Hastanesi, Nicosia, Cyprus
Introduction and Aims: Cardiovascular complications are encountered
frequently in end stage renal disease patients. Pulmonary hypertension has
been reported in dialysis patients. The aims of this study were to find out
the incidence of pulmonary hypertension, to determine the possible risk
factors of pulmonary hypertension in dialysis patients and to find out the
differences between two dialysis modalities.
Methods: Sixty seven haemodialysis patients (F/M) and nineteen peritoneal
dialysis (F/M) patients were clinically evaluated for 24 months. Twenty-two
of haemodialysis (HD)patients (32.8%) and 5 of peritoneal dialysis (PD)
patients (26.3%) had diabetes mellitus. All patients had undergone Doppler
echocardiograpy (pulmonary arterial pressure and left ventricular dimen-
sions were evaluated) at least twice and haemodialysis patients were also
undergone a Doppler USG of the arterio venous fistula (location and flow rate
were evaluated) during the follow-up period. Pulmonary hypertension (PHT)
was diagnosed when the mean of two levels of pulmonary arterial pressure
(PAP) exceeded 35mmHg. Laboratory tests done included serum cholesterol,
calcium, phosphorous, intact PTH, hemoglobin and ferritin levels.
Results: The incidence of PHT was 26.8% in HD and 31.6% in PD patients
(p>0.05). The mean PAP was 23.6 mmHg in HD while it was 24.8% in PD
patients. LVH was seen in 32.2% of HD and 36.4% of PD patients (p>0.05).
Diabetes mellitus was a risk factor for patients under both types of dialysis
(p=0.03). Serum levels of ferritin (p=0.04) was found to be significantly
related to PHT while iPTH, hemoglobin and serum cholesterol levels were
found to be unrelated in both HD and PD patients. Locations and flow rate
of AVF of HD patients were also related with PHT. Patients with brachial
fistulas were more prone to PHT but the difference was insignificant while
the flow rate of the fistulas was significantly related with PAP (p=0.04).
Conclusions: In conclusion in this study PHT was found to be frequent in
both dialysis types. Although the incidence was higher in PD patients the
difference was insignificant. This higher incidence in PD patients in spite
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of AVF in HD patients which is supposed to be a risk factor in some studies
may be attributed to higher fluid overload in PD patients as can be seen
with their higher incidence of LVH. Diabetes mellitus was found to be a
risk factor for PHT which may be attributed to higher incidence of vascular
atherosclerosis in dialysis patients. Serum ferritin levels which is a marker
for inflammation was also found to be significantly related with PHT in
dialysis patients. The significant effect of higher flow rates of AVF may be
a result of increased cardiac output.
SaP243 PROGNOSTIC VALUE OF CAROTID INTIMA MEDIA
THICKNESS AND WALL PLAQUES IN HEMODIALYSIS
PATIENTS
Jose Emilio Sanchez 1, Patricia Delgado 1, Ana Gonzalez-Rinne 1,
Domingo Hernandez 2, Victor Lorenzo 2. 1Nephrology, Hospital
Tamaragua, Puerto de la Cruz, Tenerife, Spain; 2Nephrology, Hospital
Universitario de Canarias, La Laguna, Tenerife, Spain
Introduction and Aims: Cardiovascular disease and other complications of
atherosclerosis are the most common cause of death in patients with chronic
renal failure in maintenance hemodialysis (MHD). Carotid ultrasonography
is a simple no invasive tool to investigate the vascular system, by means of
intima media thickness (IMT) measurement and carotid wall plaques. Aim
of the study was to determine IMT and its possible clinical relationships
and to investigate whether IMT would predict cardiovascular morbidity and
mortality in patients in MHD.
Methods: We studied 60 MHD patients (age 68±13 years, 48% male,
50% diabetics, time on MHD 32±11 months) and a control group of
274 people matched for age and sex. Follow-up period was 56±10
months. Measurements: Demographic and clinical data, serum levels of
homocysteine (tHcy), folic acid (FA) and B6 and B12 vitamins. IMT was
measured by high-resolution B-mode ultrasonography.
Results: IMT was higher in MHD patients than in those in the control
group (0,947±0,308 vs 0,619±0,176 mm; P<0.001). IMT was related with
age (r = 0.268, P = 0.038), diabetic (r = 0.650; P<0.001) and hypertensive
condition (r = 0.333, P = 0.012), but not wih lipids, tHcy or FA. Similar
findings were found with the presence or not of carotid plaques but serum
LDL-cholesterol levels were also related (r= 0.280, P=0.031). Patients who
suffered from coronary artery disease, peripheral artery disease or stroke had
higher IMT than those without those events (1.156±0.371 vs 0.875±0.285
mm, P<0.001; 1.205±0.374 vs 0.911±0.231 mm, P=0.007; 1.195±0.264
vs 0.844±0.251, P<0.001 respectively). Something similar ocurred with
the presence of plaques.
During the follow-up period 36 patients (60%) died, 67% of them due to
cardiovascular causes. IMT was higher in patients who expired than those
who survived (1,020±0264 vs 0,858±0.334 mm; P = 0.044). The survival
rate during the observation was significantly lower in the final IMT fourth
(20%) than in the first (72%) (P=0.014).
Conclusions: These findings suggests that measurement of carotid IMT
and the presence of wall plaques are useful tools to predict cardiovascular
events and mortality in patients in MHD.
SaP244 INCREASED RATIO OF EXTRACELLULAR TO TOTAL
BODY WATER (ECW/TBW) IS RELATED TO
COMORBIDITY AND FLUID OVERLOAD RATHER LOSS
OF LEAN BODY MASS IN HAEMODIALYSIS (HD)
PATIENTS
Cian Chan 1, Simon J. Davies 1, Christopher McIntyre 2, David Smith 3,
Patrik Spanel 3. 1Department of Nephrology, University Hospital of North
Staffordshire, Stoke on Trent, Staffordshire, United Kingdom; 2Centre for
Integrated Systems Biology & Medicine, School of Medical & Surgical
Sciences, DCGH, Derby, Derbyshire, United Kingdom; 3Institute of Science
and Technology in Medicine, University of Keele, Stoke on Trent,
Staffordshire, United Kingdom
Introduction and Aims: The application of Bioelectrical Impedance Anal-
ysis (BIA) has shown that increased ECW/TBW is associated with poor
outcome in HD patients. It is less clear whether this is attributable to fluid
overload leading to expanded ECW or loss of lean body mass leading to
low TBW. The aim of this study was to combine relative measures of
TBWBIA and the ECW/TBW ratio as measured by a multi-segmental and
multi-frequency BIA device (InBody S20, Biospace, Korea) with abso-
lute determination of TBW obtained in the dialysis unit from Deuterium
Dilution using breath analysis using an on-line Flowing Afterglow Mass
Spectrometer (Transpectra, UK).
Methods: 59 HD patients were studied (17 female, mean age 58.4± 16.1
years, mean BMI 27±5.4). Body composition was determined post-dialysis.
Co-morbidity was documented using the validated Stoke Co-Morbidity
Index. SGA showed 84.7% of the patients were well-nourished and 15.3%
were mildly malnourished.
Results: The mean post-dialysis ECW/TBW was 0.39±0.01 and was signifi-
cantly associated with increasing age (R=0.678, p< 0.001) and co-morbidity
grade (ANOVA p= 0.000) (Fig. 1). The Pearson’s correlation between TBWD
and TBWBIA was 0.94, p< 0.001. The mean difference between the ab-
solute TBWD and TBWBIA was 1.61±3.09L (95% CI 0.80 to 2.41, p<
0.001). This difference between methods was greater in patients with higher
ECW/TBW (R=0.404, p=0.002), in older patients (R=0.282, p=0.031), in
patients with higher co-morbidity scores (R=0.474, p<0.001) and increased
BMI (R=0.26, p=0.049). There was an incremental effect of co-morbidity
on the difference between TBWD and TBWBIA (ANOVA p= 0.004) (Fig. 2).
Fig. 1
Fig. 2
Conclusions: In conclusion, by combining relative and absolute measures of
body composition this study has shown that the increased ECW:TBW ratio
observed in more co-morbid but not severely malnourished HD patients is
associated with a higher TBW than that predicted from BIA. This suggests
that there is added value in the absolute measurement of TBW when
assessing fluid status.
SaP245 A COMPARATIVE STUDY OF THE EFFECTS ON PULSE
WAVE VELOCITY (PWV) IN HEMODIALYSIS (HD)
PATIENTS TREATED BY SEVELAMER WITH LOW DOSE
CALCIUM CARBONATE OR CALCIUM CARBONATE
ALONE
Kazuhiko Shibata 1, Tamio Iwamoto 2, Tomoyuki Murakami 2,
Shinji Hirawa 3, Gen Yasuda 3, Yoshiyuki Toya 4, Satoshi Umemura 4,
Hidehisa Satta 5, Toshihiro Kimura 6, Naoaki Koguchi 1, Seiiti Kawata 6.
1Toshin Clinic, Yokohama, Kanagawa, Japan; 2Internal Medicine,
Yokohama Minato Redcross Hospital; 3Internal Medicine, Yokohama City
University Medical Center; 4Internal Medicine, Yokohama City University
Hospital; 5Yokodai Central Clinic; 6Yokohama Minami Clinic
Introduction and Aims: Cardiovascular disease is a major cause of mor-
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bidity in patients with end-stage renal failure. Increasing evidence suggests
that prolonged use of calcium carbonate increases the total body calcium
load, and potentially increases the risk of cardiovascular and soft tissue
calcification. Sevelamer is the first phosphate-binding agent that is non-
absorbed, calcium-free, and metal-free. It may also attenuate coronary and
aortic calcification and has a number of other beneficial effects on lipid
metabolism. On the other hand, arterial stiffness measured by pulse wave
velocity (PWV) is an independent risk factor for morbidity in end stage
renal failure patients, and treatment with sevelamer was reported to attenu-
ate the progressive increase in PWV in HD patients.The present study was
performed to assess the effect of sevelamer administration on PWV in HD
patients treated with calcium carbonate.
Methods: We performed a randomized clinical trial to compare the effect
of calcium carbonate alone and sevelamer with low dose calcium carbonate
on PWV. 44 HD patients (24 men and 20 women; mean age 63±6 years;
mean HD duration 6.3±2.7 years), who had been treated with calcium
carbonate as a phosphate binder, were enrolled into the study. The patients
were randomly divided into the sevelamer with low dose calcium carbonate
group (group A) and calcium carbonate alone group (group B). PWV
was compared before and at the end of 2-year therapy of both. Serum
biochemistry parameters were also assessed.
Results: All the variations found were evaluated through mean values ±
SD, t-tests. In group A, the dose of calcium carbonate could be reduced
significantly from 2.8±1.0 g/day to 1.2±1.1 g/day with serum phosphate
values maintained below 6 mg/dl by the addition of 2.5±0.7 g/day sevelamer.
Only in this group, intact parathyroid hormone rise from 94.9±111.2 pg/mL
to 188.2±168.4 pg/mL (P<0.05),. However, there was not significant
difference in PWV from 1874±659 to 1939±378 cm/sec (P=0.7). In group
B, the dose of calcium carbonate needed to be administered 1.9±0.8 g/day to
maintain serum phosphate values below 6 mg/dl. There was not significant
difference in PWV from 2094±697 cm/sec, to 1923±501 cm/sec (P=0.27).
In both group serum calcium, phosphate and calcium x phosphate product
remained unchanged.
Conclusions: The dosage of calcium carbonate was successfully reduced
by adding sevelamer to maintain serum phosphate levels below 6 mg/dl.
However, there was not the improvement in PWV, suggesting that more
intensive long-term study is essential to evaluate the effects of sevelamer on
PWV.
SaP246 LOW GLOMERULAR FILTRATION RATE IN PATIENTS
PRESENTING WITH ACUTE CORONARY SYNDROME:
IS EARLY CKD A RISK FACTOR FOR CAD?
Sree Bhushan Raju, Jyotsna Madduri. Nephrology and Cardilogy, Nizam’s
Institute of Medical Sciences, Hyderabad, Andhra Pradesh, India
Introduction and Aims: Coronary artery disease(CAD) is the commonest
cause of mortality in patients with CKD. Wheter the patients with early fall
in Glomerulo filtration rate (GFR) are at risk to develop CAD is not known.
We analysed the effect of Coronary artery disease on GFR in patients
presenting with acute coronary syndrome (ACS).
Methods: We analyzed 305 consecutive patients admitted to acute coronary
care unit over 6 months with the diagnosis of acute coronary syndrome
and undergoing coronary angiogram (CAG). Diagnosis of acute coronary
syndrome was made with classical history recent onset or rest angina with
or without ECG changes. GFR was estimated by Creatinine clearance (Ccr)
according to Cockcroft-Gault formula.
Results: Among 305 patients males were 269(88.2%) and females were
36(11.8%) with mean age of 52±10 (25-81) years. Hypertensives were168
(55%), 99(32.5%) were diabetics, 137(45%) were smokers and family
history of CAD was present in 30(9.8%) patients. Echocardiogram showed
normal left ventricular (LV) function in 154(50.5%), mild LV dysfunc-
tion(LVD) in 54(17.7%), moderate LVD in 85(27.9%), and severe LVDin
12(3.9%) patients. CAG showed border line CAD (> 30% but < 50%
stenosis in one or more coronary arteries) in 12(3.9%), insignificant CAD
(>50% but <70% stenosis) in 34(11.1%), significant CAD (>70% stenosis)
in 221(72.5%) patients and normal coronaries in 38(12.5%) patients. Mean
GFR in all was 70±21(18.6-128.8) ml/min. GFR in normal CAG was
78±21ml/min, with borderline CAD was 68±21ml/min, with insignificant
CAD was 75±21 ml/min and with significant CAD patients was 59±19
ml/min. Analysis of variance between CAD and creatinine clearance was
significant (p < 0.02) more so when creatinine clearance of patients with
significant CAD (221) was compared with creatinine clearance of those
with insignificant CAD (84) using unpaired student t test. (p<0.004). GFR
correlated with the degree of LV dysfunction (p<0.01).
Conclusions: Low GFR is common in patients with significant obstructive
CAD presenting with ACS. This suggests that the patients with even early
CKD are more at risk to develop significant CAD.
SaP247 ProBNP, BNP, AND NT-proBNP CIRCULATING LEVELS
ARE ALTERED BY HEMODIAFILTRATION BUT STILL
CORRELATE WITH VENTRICULAR FUNCTION IN
CHRONIC HEMODIALYSIS PATIENTS
Anne-Sophie Bargnoux 1, Kada Klouche 2, Jeannette Fareh 3,
Isabelle Barazer 4, Anne-Marie Dupuy 1, Helene Leray-Moragues 5,
Sylvie Villard-Saussine 3, Isabelle Giuliani 6 , Jean-Paul Cristol 1,
Bernard Canaud 5. 1Biochemistry Laboratory, Lapeyronie University
Hospital, Montpellier, France; 2Metabolic Intensive Care, Lapeyronie
University Hospital, Montpellier, France; 3FRE CNRS 3009, Montpellier,
France; 4Biochemistry Laboratory, Hospital Center, Beziers, France;
5Nephrology and Hemodialysis, Lapeyronie University Hospital,
Montpellier, France; 6Bio-Rad Laboratories, Marnes-La-Coquette, France
Introduction and Aims: Brain natriuretic peptide (BNP) is released pri-
marily as a prohormone proBNP that is enzymatically cleaved into the
active hormone BNP and the inactive N terminal propeptide (NT proBNP).
Increased circulating BNP and NT-proBNP, and in a lesser extent proBNP,
have been associated with left ventricular dysfunction and with a poor out-
come of patients with end stage renal failure. More recently, the prohormone
proBNP determination was also available. However, the levels of circulating
peptide values may be not only dependent on cardiac function and dimen-
sions but also on renal function, fluid volume, and their removal by dialysis
procedure including hemodiafiltration (HDF). The purpose of this study was
(i) to assess in chronic dialysis patients the basal levels of BNP, NT-proBNP
and the prohormone proBNP and their correlation with clinical and echocar-
diographic data (ii) to investigate their changes after a session of HDF.
Methods: 31 dialysis patients in maintenance HDF for at least 6 months
without clinical or echocardiographic evidence of cardiac failure were in-
cluded. Baseline clinical and echocardiographic parameters were collected.
Pre and post-HDF BNP (Bayer), NT-proBNP (Dade Behring) and proBNP
(Bio-Rad) plasma concentrations were measured. Correlations between
echocardiographic measurements and basal circulating peptides, and be-
tween changes in peptide values and changes in fluid volume after HDF
were investigated.
Results: Baseline plasmatic levels of natriuretic peptides were el-
evated (BNP=517±840 pg/ml, NT-proBNP=5340±6132 pg/ml and
proBNP=3569±4683 pg/ml) and correlated with left auricular diameter
(r2=0.25 for BNP, r2=0.25 for NT-proBNPand r2=0.14 for proBNP) and
left ventricular mass index (r2=0.19 for BNP, r2=0.17 for NT-proBNPand
r2=0.12 for proBNP). The HDF session led to a significant decrease of 39%
for BNP, 59% for NT-proBNP and 36% for proBNP. This decrease was not
correlated to post-HDF fluid removal or weight decrease.
Conclusions: Despite their elimination by hemodiafiltration, BNP, NT-
proBNP and proBNP could be potential markers of left ventricular function
in chronic renal failure patients on maintenance dialysis. According to our
results, their cut-off values need to be reevaluated by further larger clinical
trials.
SaP248 INFLAMMATION-RELATED IMBALANCE IN BONE
MORPHOGENETIC PROTEINS (BMPs) PRODUCTION
MAY FAVOUR THE PROGRESSION OF CARDIO-
VASCULAR DISEASE IN DIALYSIS PATIENTS (PTS)
Giovanni Pertosa, Giuseppe Dalfino, Silvia Porreca, Simona Simone,
Gianluigi Zaza, Roberto Corciulo, Stefania Pietanza, Francesco
Paolo Schena, Giuseppe Grandaliano. Department of Emergency and
Organ Transplantation, Renal, Dialysis and Transplant Unit, University of
Bari, Bari, Italy
Introduction and Aims: Inflammation may directly modulate vascular cal-
cification (VC) in end stage renal disease pts leading to high cardiovascular
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mortality. There are evidences of BMP2 and 7 involvement in VC process,
but it is still unclear whether uremic condition and chronic inflammatory
status can regulate the expression of these proteins.
Methods: The relationship between BMP-2 and BMP-7 (ELISA, R&D
and RayBiotech, respectively), high sensitive C-reactive protein (hsCRP),
Fetuin-A (ELISA, Biovendor) serum levels and carotid intima-media thick-
ness (cIMT, B-mode ultrasonography) were studied in 50 uremic pts, stably
on hemodialysis (HD) (25 pts, mean age 60.5 years; dialytic age 49.5
months), or peritoneal dialysis (PD) (25 pts, mean age 59.1 years; dialytic
age 45.4 months). The effect of inflammation on BMPs expression was
evaluated in vitro in Eahy926 cells (an immortalized endothelial cell line)
by RT-PCR and confocal microscopy.
Results: Significantly higher BMP-2 serum levels were found in HD
compared to PD pts and normal controls (C) (C 8.1±2.4; HD 65.1± 13;
PD 28.5±2.4 pg/ml; p<.002). On the contrary, lower BMP-7 (C 451.6±
59.9; HD 36.6±6.1; PD 295.6±60.1 pg/ml; p<.0001) and Fetuin-A (C
375.0±78.2; HD 243.5±42.0; PD 290.7±58.4 mg/ml; p<.0001) serum
concentrations were observed in HD pts as compared to PD pts and C.
At univariate analyses BMP-2 serum levels were inversely correlated with
Fetuin-A (r=-.38,p<.02) and positively correlated with CRP (r=.3;p<.01)
and cIMT values (r=.4; p=.003). On the contrary, BMP-7 was directly
correlated with Fetuin-A (r=.35, p=.04) and inversely associated with CRP
(r=-.7; p<.0001) and cIMT (r=-.6; p<.0001). In a multiple regression model,
cIMT was independently correlated with BMP-2, BMP-7 and CRP. Finally,
an increased BMP-2 and a lower BMP-7 gene and protein expression were
observed in Eahy cells upon incubation with TNF-a. (100U/ml), a powerful
pro-inflammatory cytokine.
Conclusions: In conclusion, inflammation-related high BMP2 serum levels
along with low BMP7 and Fetuin-A concentrations are strictly correlated
with progression of atherosclerotic lesions in dialysis pts.
SaP249 PREDICTIVE VALUE OF BOTH BNP AND NT-proBNP IS
ENHANCED BY CRP LEVELS IN AN HEMODIALYSIS
POPULATION
Anne-Sophie Bargnoux 1, Nathalie Terrier 1, Isabelle Barazer 2,
Isabelle Jaussent 3, Kada Klouche 4, Anne-Marie Dupuy 1,
Bernard Canaud 5, Jean-Paul Cristol 1 . 1Biochemistry Laboratory,
Lapeyronie University Hospital, Montpellier, France; 2Biochemistry
Laboratory, Hospital Center, Beziers, France; 3Inserm, E361, Montpellier,
France; 4Metabolic Intensive Care, Lapeyronie University Hospital,
Montpellier, France; 5Nephrology and Hemodialysis, Lapeyronie
University Hospital, Montpellier, France
Introduction and Aims: BNP and NT-proBNP levels are considered as
an important diagnostic tool in congestive heart failure. They could be of
predictive value in hemodialysis (HD) patients. However the relationship
between cardiac natriuretic peptides levels and the HD-induced inflamma-
tory state remains poorly investigated. The aim of this study was to explore
the prognostic relevance to all-cause and cardiovascular mortalities in HD
patients of BNP, NT-proBNP in combination with C-reactive protein (CRP).
Methods: We measured BNP, NT-proBNP, CRP at baseline (October to
November 2001) in 130 HD patients [median age 69.0 years (range 23.4-
87.7), 71 females, 59 males]. Patients were followed prospectively for
mortality until January 2005. The adjusted relative risks (RRs) of death
and 95% confidence intervals (CIs) were estimated using Cox proportional
hazard models.
Results: During follow up, 36 patients died, 58.3% due to cardiac causes.
Elevated BNP and NT-proBNP were associated with increased total and
cardiovascular mortality [RR adjusted for age, gender and dialysis vintage
8.9 (2.0-39.7) for the third tertile of BNP versus the first tertile and
6.8 (1.9-24.7) for the third tertile of NT-proBNP versus the first tertile].
Moreover the combination of elevated CRP (>10.5mg/l) impaired the HD
survival rate especially the cardiovascular mortality. The combination of
CRP>10.51mg/l and BNP>75pg/ml was associated with an increase in
total (RR 5.70, 95% CI 2.38 to 13.67; p<0.0001, after adjustment for
age, gender and dialysis vintage) and cardiovascular mortality (RR 12.42,
95% CI 3.28 to 47.12; p=0.0002, after adjustment for age, gender and
dialysis vintage). Similarly, the combination of CRP>10.51mg/ml and NT-
proBNP>10204pg/ml resulted in a raise in total (RR 5.84, 95% CI 2.32 to
14.68; p=0.0002, after adjustment for age, gender and dialysis vintage) and
cardiovascular mortality (RR 20.12, 95% CI 4.24 to 95.52; p=0.0002, after
adjustment for age, gender and dialysis vintage).
Conclusions: Circulating BNP and NT-proBNP were associated with poor
outcome, especially when combined with elevated CRP, strongly supporting
their annual routine determination.
SaP250 PLASMA ADRENOMEDULLIN LEVEL PREDICTS
CEREBRO AND CARDIOVASCULAR EVENTS IN
MAINTENANCE HEMODIALYSIS PATIENTS
Keiko Nishi 1,2 , Kazuhiro Yamada 2, Shouichi Fujimoto 2 , Toshihiro Kita 2,
Shuichi Hisanaga 1, Kazuo Kitamura 2. 1Internal Medicine, Koga General
Hospital, Miyazaki, Japan; 2Circulatory and Body Fluid Regulation,
Faculty of Medicine, University of Miyazaki, Miyazaki, Japan
Introduction and Aims: Adrenomedullin (AM), a vasodilative and natri-
uretic peptide, is correlated with cardiovascular condition and elevated in
hemodialysis (HD) patients. Although the high prevalence of cerebro- and
cardiovascular events (CCVE) in HD patients has been explained by several
risk factors, it is still unknown whether the measurement of AM predicts
subsequent CCVE in maintenance HD patients.
Methods: A total of 89 HD outpatients (age, 58.0±12.9 years, mean ±
SD; male/female, 54/35; HD vintage, 97±84 months) were followed up
prospectively for 53±13 months in a single dialysis center. At the start of
this study, AM (IRMA kit, Shionogi Pharmaceutical Co.), high sensitivity
C-reactive protein (hs-CRP) (N High Sensitivity CRP kit, Dade Behring
Inc.), hemoglobin, albumin and lipids profiles were measured in blood
samples taken just before HD treatment, in addition to blood pressure
(BP) and pulse wave velocity (PWV) using form PWV/ABI (Colin Co.).
The presence of death and hospitalization due to CCVE had been checked
during the follow-up periods, and the prognostic values were tested by
Cox’s regression analysis.
Results: Plasma AM, serum hs-CRP and albumin were 27.5±7.8 fmol/mL,
1.87±3.53 mg/L, 3.7±0.3 g/dL at baseline, respectively. Systolic BP and
PWV were 155±19 mmHg and 1779±390 cm/sec, respectively. During the
follow-up periods, 7 patients dropped out (2 with a renal transplantation
and 5 with a transfer to another dialysis center) and 7 had died. Twenty-two
patients had been hospitalized for and/or died of CCVE: new episodes
of ischemic (n = 8) and non-ischemic (n = 8) heart disease, cerebral
hemorrhage (n = 5) and infarction (n = 1). In stepwise Cox’s regression
analysis, CCVE was associated with age (per 10 years; relative risk [RR],
1.828; 95% confidence interval [95% CI], 1.241 to 2.6923; p = 0.0022) and
plasma AM level (per 10 fmol/mL; RR, 1.731; 95% CI, 1.016 to 2.951;
p = 0.0436). Divided into 3 groups by plasma AM levels (group I, <20
fmol/mL; group II, 20– 30 fmol/mL; group III > 30 fmol/mL), higher rate
of CCVE in group III was observed compared with that in group II (RR,
4.354; 95% CI, 1.513 to 12.525; p = 0.0064; adjusted for age). There was no
significant association between CCVE and hs-CRP or PWV in this study.
Conclusions: In maintenance HD patients, subsequent cerebro- and cardio-
vascular events may be predicted by the measurement of plasma AM.
SaP251 THE NITRIC OXIDE IN PATIENTS TREATED BY
MAINTENANCE HEMODIALYSIS
Dorota Formanowicz 1,2, Irena Pietrzak 1. 1Dept. of Nephrology,
Transplantology and Internal Medicine, Poznan University of Medical
Scieces, Poznan, Poland; 2Dept. of Clinical Biochemistry, Poznan
University of Medical Scieces, Poznan, Poland
Introduction and Aims: Atherosclerosis is a very serious problem, espe-
cially in hemodialysed patients, because the frequency of this phenomenon
in these patients is much higher than it is in general population. The
endothelial nitric oxide (NO) is considered as an important atheroprotective
mediator, and acquired defects in generation of NO associated with car-
diovascular risk factors cause endothelial dysfunction and may lead to the
development of atherosclerosis. The aim of this study was the assessment
of NO serum concentration and finding factors that may influence it serum
concentration in group of patients treated by maintenance haemodialysis
(mHD).
Methods: To this study we enrolled 66 patients (20 of them had coronary
artery disease, 12 suffered from diabetes mellitus) treated by mHD (mean
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duration of HD 47.35±37.12 months). HD procedures were performed 3
times a week for 4 hours with polysulphone capillary dialyzers. The results
from mHD patients were compared with reference values which were
obtained from 20 healthy volunteers (HV). Serum samples were drawn at
the start of of the second HD from fasting patients and from fasting HV.
The nitrite/nitrate (NO), vascular endothelial growth factor - 2 (VEGFR2),
amino-terminal pro-brain natriuretic peptide (NT-proBNP) and soluble IL-6
receptor (sIL-6R), concentration were evaluated by the ELISA method.
The concentrations of creatinine, total cholesterol, LDL-cholesterol and
triglycerides were estimated by the routine laboratory tests.
Results: In mHD patients both NO (233.66±16.07 μmol/l) and VEGFR-2
(10012,3±4316,44 pg/ml) were slightly decreased but with no statistical
significance if compared to HV: NO (260.11±21.24 μmol/l), VEGFR-2
(13745.35±5273.27 pg/ml). Whereas the serum concentration of NT-
proBNP (152.2±68.6 fmol/ml) and sIL-6R (8051.48±2344pg/ml) were
significantly higher (p=0.01, p=0.03, respectively) in comparison to HV:
NT-proBNP (35.6±21.3 fmol/ml) and sIL-6R (2615.53±733.97 pg/ml).
Total cholesterol, LDL-cholesterol and TG were slightly (with no statistical
significance (p=0.07)) decreased in mHD patients. Serum concentration of
NO inversely correlated with the presence coronary artery disease (r=-0.2,
p=0.02), with the time of HD treatment (r=-0.235, p=0.004), and with
serum concentration of total cholesterol (r=-0.232, p=0.004). The slightly
inverse correlations but with weak statistical significance between NO and
VEGFR2 (r=-0.15, p=0.058) was observed. There were no statistically
significant correlations between NO and NT-proBNP, sIL-6R, triglicerides
and serum creatinine.
Conclusions: mHD patients shoved the propensity to the slightly lower
serum concentration of nitric oxide. High serum NT-proBNP concentration
confirms the increased risk of cardiovascular event in examined patients.
This study suggest an important relationship between the release of NO and
the duration of HD treatment and serum concentration of total cholesterol.
Moreover, we found that this parameter may be slightly influenced by the
regulation of VEGF-mediated blood vessel growth and development.
SaP252 SERUM VCAM-1 AND ICAM-1 INDICATED A DIFFERENT
PATTERN BETWEEN SHUNT STENOSIS AND
ARTERIOSCLEROSIS OBLITERANS COMPLECATED
HEMODIALYSIS PATIENTS
Osamu Saito, Atsushi Kotoda, Manabu Ogura, Kousuke Okuda,
Eiji Kusano. Nephrology, Jichi Medical University, Shimotsuke, Tochigi,
Japan
Introduction and Aims: Shunt stenosis is known as a life threatening factor
for hemodialysis patients. In addition, some patients repeat shunt stenosis
frequently. However, the mechanism of shunt stenosis has not elucidated.
For coronary artery bypass grafting (CABG), graft occlusion of saphenous
vein happened much more frequently than that of internal thoracic artery.
Previous study showed vein grafting was weak against the blood pressure
and the damage of their endothelial layer caused more severely than that
of arterial grafting. For shunt vessels, stenosis occurred mainly on the
connecting vein like a coronary vein grafting. The present study was
undertaken to determine serum adhesion molecules levels in HD patients
with shunt stenosis and arteriosclerosis obliterans (ASO).
Methods: Hundred nine shunt stenosis, 28 ASO and 50 age, gender and
duration of HD matched control hemodialysis subjects were examined.
Shunt stenosis determined the history of shunt occlusion or failure beyond 3
month of the operation day. The diagnosis of ASO was derived from Ankle
Brachial Index (ABI) less than 0.90, and stenotic or obstructive change
in angiogram. As parameters of adhesion molecules, we chose ICAM-1
and VCAM-1 and as an anti-sclerotic parameter, we chose adiponectin
(ADN) respectively. The serum levels of ICAM-1, VCAM-1 and ADN were
determined with ELISA. For static analysis, we use multiple regression
analysis first and then use Fisher analysis for group comparison. P value
less than 0.05 determined significant.
Results: In shunt stenosis group, increment of VCAM-1, decrement of
ICAM-1 and ADN showed the significance by the multiple regression
analysis. (p<0.001, p<0.001, p<0.005 respectively) on the other hand,
ASO group also indicate increment of VCAM-1, decrement of ICAM-1 and
ADN significantly (p<0.05, p<0.05, p<0.001 respectively), however, the
value of regression was less than that of shunt stenosis group. For group
comparison, serum ICAM-1 levels was 191±24 ng/ml in the patients with
shunt stenosis, 343±54 ng/ml in the patients with ASO and 470±31 ng/ml
in control subjects. (p<0.01 among each groups) Serum VCAM-1 levels
was 3255±200 ng/ml in shunt stenosis group and 3032±316 ng/ml in ASO
group and 2550±149 ng/ml in control respectively. (p<0.01 only between
shunt stenosis and control subjects).
Conclusions: The present results indicate that hypoadiponectinemia and
decrement of ICAM-1 are independent risk factors for both shunt stenosis
and ASO in hemodialysis patients. For shunt stenosis, elevation of VCAM-1
is also another risk factor and suggests a different mechanism of ASO in
hemodialysis patients.
SaP253 CORRELATIONS OF ARTERIAL STIFFNESS, ACE GENE
I/D AND COLLAGEN1A1 GENE -1245G/T
POLYMORPHISM IN PATIENTS WITH END-STAGE RENAL
DISEASE
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Introduction and Aims: Arterial stiffness (AS) is an independent predictor
of cardiovascular morbidity and mortality in patients with end-stage renal
disease (ESRD). Structural changes in the vessel wall, like transformation
of the collagen network and plaque formation can lead increased AS, a
process, which can be modified by ACE-system. Human atherosclerotic
lesions contain collagen type 1, which plays a pivotal role in atherosclerotic
plaque stability. In contrast, the normal coronary arteries do not express
this type of collagen. In our study, we evaluate the correlation between the
parameters of AS, like augmentation index (AI) and pulse wave velocity
(PWV), the ACE gene I/D and collagen type 1 A1 gene (COL1A1) -1245G/T
polymorphism in ESRD patients.
Methods: In 81 patients on hemodialysis (HD) therapy, AS parameters
(AI and PWV) were calculated twice using PulsePen device, both before
and after HD procedure. COL1A1 and ACE gene polymorphisms were
evaluated by RFLP techniques.
Results: Mean predialysis PWV (prePWV) and postdialysis PWV (post-
PWV) were 11.0±2.9 and 11.6±2.9 m/s (P=0.0001), mean predialysis AI
and postdialysis were 23.5±12.2 and 22.1±12.4% (NS), respectively. We
found no correlation between the polymorphisms and prePWV or postPWV.
The same was found in case of AI. In contras, significantly different
genotype pattern was found in case of collagen 1A1 gene in HD patients
compared to healthy controls. The “ss” genotype of the COL1A1 gene was
found to be significantly more frequent in HD patients, as compared to the
control (9/94 vs. 7/212, p=0.01).
Conclusions: Our results suggest, that the studied polymorphisms of the
ACE and COL1A1 genes has no significant predictive value for AS.
Although, the different genotype pattern of the collagen type 1 A1 gene
in HD patients - compared to controls - might be related to their higher
propensity for vascular complications.
SaP254 EFFECTS OF SIMVASTATIN ON SOLUBLE MARKERS OF
INFLAMMATION AND APOPTOSIS IN PATIENTS ON
CHRONIC HAEMODIALYSIS (HD)
Dimitrios Kirmizis, Aikaterini Papagianni, Anna-Maria Belechri,
Dimitrios Memmos. University Department of Nephrology, Hippokratio
General Hospital, Thessaloniki, Greece
Introduction and Aims: End-stage renal disease is considered to be a state
of chronic inflammation. Emerging data reveal that HMG-CoA reductase
inhibitors, beyond their lipid-lowering effects, exert pleiotropic and immune-
regulatory actions as well. The purpose of the present prospective trial was
to study the effects of a 6 month use of the HMG-CoA reductase inhibitor
simvastatin on chronic inflammation in patients on HD. Serum levels of CRP,
intracellular and vascular cell adhesion molecules (ICAM-1 & VCAM-1,
respectively), E-selectin and monocyte chemoattractant protein (MCP-1)
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were determined as markers of inflammation, and Fas and Fas-ligand (FasL)
as markers of apoptosis.
Methods: We studied prospectively 21 patients (10 males, mean age 60
years, range 30-77) stabilized on HD (mean duration 63 months, range
7-242). In all patients 10mg of simvastatin tablets per day were prescribed
for a period of 6 months. CRP was measured with the use of nephelometry.
sICAM-1, sVCAM-1 and E-selectin were determined with the use of ELISA.
All measurements were repeated at baseline, 3 and 6 months. Student’s
t-test and one-way ANOVA analysis with post-hoc multiple comparisons
were used for the comparison of the levels of the parameters at different
intervals.
Results: A significant reduction was found at 3 and 6 months com-
pared to baseline levels in total cholesterol (184.7±41 and 170.1±44
vs 236.1±40.7mg/dL, p=0.003 and p<0.0001, respectively) and LDL
(105.5±37 and 102.9±41 vs 152.5±32mg/dL, p<0.001 and p<0.001, re-
spectively). Serum CRP levels in 6 months were also decreased compared
to baseline (3.44±0.7 vs 9.25±8.3 mg/L, p=0.012). At 3 and 6 months, a
decrease in sICAM-1 was found compared to baseline (450.9±162.0 and
348.5±104.1 vs 498.55±133.75 ng/mL, p=NS and p=0.005, respectively).
Similarly, a significant reduction at 3 and 6 months compared to base-
line was noticed in sVCAM-1 levels (2270.9±680.7 and 1773.82±506.7
vs 2553.9±732.0 ng/mL, p=NS and p=0.002, respectively). No signifi-
cant differences were found between baseline, 3 and 6 months in the
levels of MCP-1 and E-selectin. Fas was found decreased at 3 and 6
months compared to baseline (20968.7±5824.4 and 17609.8±2987.2 vs
21128.8±6161.3 pg/mL, p=NS and p=0.03, respectively). FasL showed a
decrease as well at 3 and 6 months compared to baseline, which however did
not reach statistical significance (92.6±40.3 and 91.6±36.1 vs 100.9±31.4
pg/mL, p=NS and p=NS, respectively).
Conclusions: A 6 month use of simvastatin, even at low dose, resulted
in a significant lowering of CRP, ICAM-1, VCAM-1, and Fas but not
E-selectin, MCP-1 or FasL levels, in parallel to the lowering in total and
LDL cholesterol levels. These effects might be of potential therapeutic
significance for the prevention of atherosclerosis in this patient group.
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SYSTOLIC AND DIASTOLIC FUNCTION ASSESSED BY
DOPPLER TISSUE IMAGING IN DIALYSIS PATIENTS
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Introduction and Aims: The presence of right ventricular systolic dysfunc-
tion is known to significantly worsen the prognosis of patients with heart
failure. However, the prognostic impact of right ventricular diastolic dys-
function and of its combination with right ventricular systolic dysfunction
and with other prognostic markers has not yet been systematically studied in
dialysis patients. The aim of this study was to assess the prognostic impact
of combined right ventricular systolic and diastolic dysfunction in patients
with heart failure due to ischemic or idiopathic dilated cardiomyopathy.
Methods: The study included 152 patients on periodic hemodialysis
(mean left ventricular ejection fraction of 29,2%) from 31 Italian clinics
belonging to a clinic network using a prospective database (EuCliD).
All patients underwent clinical and laboratory examination and standard
echocardiography completed by Doppler tissue imaging of the tricuspid
annular motion. They were followed up for a mean period of 18 months.
Results: During the follow-up, there were 25 cardiac-related deaths and 38
non-fatal cardiac events (33 hospitalizations for heart failure decompensation
and 5 hospitalizations for malignant arrhythmias). The multivariate stepwise
Cox regression, the right ventricular systolic (represented by the peak
systolic tricuspid annular velocity-Sa) and diastolic (represented by the peak
early diastolic tricuspid annular velocity-Ea) function to be the independent
predictors of event-free survival or survival (p<0.01). The Sa was better
predictor for the risk of cardiac events (p<0.05), while the Ea appeared to
further distinguish patients with increased risk of early non-fatal event and
early death rather than risk of late event from those at risk. The combination
of Sa and Ea, creating the Sa/Ea categories, was the strongest predictor of
events: the Sa/Ea I category of patients (Sa>=10.8 cm s-1 and Ea>=8.9
cm s-1) had excellent prognosis; while the Sa/Ea IV category (Sa<10.8 cm
s-1 and Ea<8.9 cm s-1) was found to be at a very high risk of cardiac
events (p<0.001 vs. Sa/Ea I). Imbalanced categories of patients (Sa/Ea II
and III) with only one component (Sa or Ea) pathologically decreased were
at medium risk when assessing event-free survival. However, a significantly
better survival (p<0.05) was found in patients with Ea>=8.9 cm s-1 (Sa/Ea
I and III categories) as compared with those having Ea<8.9 cm s-1 (Sa/Ea II
and IV categories). In contrast to event-free survival, the survival pattern was
determined mainly by the Ea value with only little additional contribution
of Sa.
Conclusions: The assessment of right ventricular systolic and diastolic
function provides complementary information with a very high power to
stratify prognosis of patients with heart failure and on hemodialysis. The
combination of right ventricular systolic and diastolic dysfunction identifies
those with a very poor prognosis.
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Introduction and Aims: Left ventricular hypertrophy (LVH) is a very
common finding in end-stage renal disease patients and represents an
independent risk factor for mortality, whereas the occurrence of LVH may
share a multifactorial origin. The impact of various PTH levels on left
ventricular hypertrophy (LVH) progression in hemodialysis patients (pts) is
still ill defined.
Methods: We retrospectively evaluated 60 of 118 HD pts who underwent
echocardiography examination at baseline (B) and follow-up (F-U; 11.5±1.0
months). From the study were excluded pts with: systemic disease; valvular
disease; coronary heart disease; interdialytic body weight gain (IDBWG)
greater than 6% b.w.; abnormal systolic function (ejection fraction less
than 55%); previous parathyroidectomy. We identified three subgroups (G)
according to PTH variations throughout the observation period. Group 1 (n
= 19), with PTH values steadily < 200 pg/ml throughout the F-U; Group 2
(n = 20), with a progressive increase of PTH levels to values > 200 pg/ml,
16/20 pts received calcitriol intravenously after HD at a dose ranging from
1 μg to 3 μg twice/week; Group 3 (n = 21), with PTH levels > 200 pg/ml
and > 50% reduction after intermittent calcitriol therapy intravenously at a
dose ranging from 1 μg to 4 μg twice/week.
Results: PTH levels were correlated with LVMi (r = 0.714; P < 0.001),
LV end diastolic diameter (r = 0.464; P < 0.001), interventricular septal
thickness (r = 0.395; P < 0.01), and LV posterior wall thickness (r = 0.279;
P < 0.05). Furthermore, significant correlations were found between mean
systolic (r = 0.338, P < 0.01) and diastolic blood pressure (r = 0.353; P
< 0.01) and LVMi. Patients with baseline PTH levels > 200 pg/ml (n =
27) had a higher LVMi with respect to those with PTH < 200 pg/ml (n
= 33) (195±50 vs 135±31 g/m2; P < 0.01). In G1 LVMi did not change
during F-U. In G2 LVMi increased from 146±26 to 175±46 g/m2 (P <
0.05). In G3 LVMi decreased from 210±44 to 154±42 g/m2 (P < 0.001).
Multivariate analysis showed that PTH was the most important predictor
for the progression of LVH followed by systolic blood pressure, while we
failed to find any relationship between LVMi and IDBWG, calcitriol, serum
calcium, and hemoglobin.
Conclusions: PTH per se may play an important role in the genesis and
perpetuation of LVH, whereas partial correction of sHPT with injectable
calcitriol may determine LVH regression.
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Introduction and Aims: Cardiac autonomic dysfunction is a common
complication in patients with chronic kidney disease (CKD) and may
contribute to increased cardiovascular morbidity and mortality in this
population. Heart Rate Variability (HRV) is an established non-invasive
method for the evaluation of autonomic nervous system activity at the heart
level (CAN). Both type 2 diabetes mellitus (T2DM) and CKD have been
repeatedly shown to affect HRV and their concurrence on the same patient
results in poorer mid-term cardiovascular prognosis.
AIM: To evaluate CAN in diabetic and non-diabetic patients with stage 4
CKD, by means of HRV measurements, and to evaluate the effect of chronic
haemodialysis on the same patients 3 months after initiation of dialysis.
Methods: This was a prospective study of 100 patients divided into four
groups: Group 1: 25 patients with T2DM and CKD stage 4 (age 67±9
years, 11 men); Group 2: 25 non-diabetic patients with CKD stage 4 (age
65±7 years, 14 men); Group 3: 25 patients with T2DM but without CKD
(age 67±7 years,10 men); and Group 4: 25 healthy controls (age 65±3
years, 10 men). CAN was measured in all patients, using 24-hours ECG-
Holter monitoring with HRV analysis in both time domain [min HR interval,
maxHR, SDNN, ASDNN, SDANN, SD) and frequency domain (total power,
LF, VLF, LF/HF ratio). For the Groups 1 and 2, HRV measurements took
place before and 3 months after initiation of haemodialysis.
Results: Both time and frequency domain parameters were worse in the
Groups 1-3 in comparison with the Group 4 (p<0.05) Among Groups 1, 2
and 3 no significant differences were observed, except for the LF/HF ratio,
which was higher in Group1 in comparison with the Group 2 (p = 0.001)
and Group 3 (p = 0.02). Three months after initiation of haemodialysis,
patients in Group 2 showed improvement in several time domain parameters
(maxHR (p = 0,021), meanRR (p = 0,025), HR (p = 0,024), SDNN (p =
0,036), SDANN (p = 0,013) and SD (p = 0,032), while patients in Group
1 had improvement only in (SDANN, p = 0.04). No significant difference
was observed in the frequency domain parameters after the initiation of
haemodialysis in either study group.
Conclusions: The lack of significant difference in most of the HRV
parameters among the patients with CKD or diabetes probably reflects the
dual cause of autonomic dysfunction in these patients, namely uremia and
hyperglycaemia. Haemodialysis improved only the time domain parameters
of HRV in the non-diabetic patients with CKD but not in the patients with
diabetes and CKD. This finding suggests that diabetic patients with CKD
may have poorer prognosis in terms of cardiovascular events and overall
survival.
SaP258 IMPACT OF MYELOPEROXIDASE (MPO) ON LIPIDS
OXIDATION AND CAROTID PLAQUE FORMATION IN
HEMODIALYSIS PATIENTS (HD pts)
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Introduction and Aims: MPO is an important source of oxidative stress
in HD pts, however, associations between MPO, lipid oxidation, and
atherosclerosis in those pts are not fully evaluated.
Methods: In one hundred and eighty-six HD pts (aged 65±13 years, 58%
males, diabetes mellitus: DM 31%, HD vintage 77 months: range1.0-346),
WBC count including differential WBC, high sensitive C-reactive protein
(hsCRP), s-albumin (s-Alb), lipids (Cholesterol: chol, HDL-chol, LDL-chol,
oxidized(ox) HDL-chol, oxLDL-chol), MPO and oxα1 antitrypsin(AT) as
an activated PMN-linked oxidative stress marker were measured before
HD session. Carotid artery intima-medial thickness (IMT) was analyzed
by B mode ultrasonography and the maximum value of IMT (max IMT)
measured in the bilateral carotid artery in each patient.
Results: MPO levels were correlated with WBC (rho=0.18, p=0.01), ox
LDL-chol (rho=0.44, p<0.0001), ox HDL-chol (rho=0.32, p<0.0001), ox
AT (rho=0.60, p<0.0001) and max IMT (rho=0.25,p=0.001). Ox HDL-chol
(179.8±49.1 ng/mL versus 155.9±64.1 ng/mL, p<0.0001) and ox AT levels
(83.6±40.4 ng/mL versus 44.1±22.9 ng/mL, p<0.0001) and ox LDL-chol
(56.8±27.5 U/L versus 35.6±11.9 U/L, p<0.0001) as well as max IMT
(1.57±0.79 versus 1.18±0.4, p=0.001) were significantly increased in a
high MPO group divided by median MPO level, while HDL-chol and
LDL-cho levels did not differ between a high and a low MPO group. In
univariate model MPO, oxLDL and oxAT associated to max IMT but not for
oxHDL-chol. MPO (β=0.11, p=0.04) and ox LDL-chol (β=0.13, p=0.008)
were independently associated with max IMT by a backward stepwise
multivariate regression analysis included age, gender, DM, hsCRP, WBC,
MPO, HDL-chol, oxLDL-chol, and oxAT as independent factors (adjusted
r2=0.28). In this model ox AT tended to be linked to max IMT (β=0.09,
p=0.08).
Conclusions: In conclusion, MPO seems to influence lipid oxidation and
plaque formation as a consequence of excess oxidative stress in HD pts.
SaP259 HEMODIALYISIS EFFECTS ON PULSE WAVE ANALYSIS:
MEMBRANE BIOINCOMPATIBILITY AND
ULTRAFILTRATION EFFECTS
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Introduction and Aims: Cardiovascular disease is a major cause of morbi-
mortality in dialysis patients. Among other, repetitive endothelial damage
from dialysis membrane bioincompatibility has been proposed as a con-
tributing factor of accelerated atherosclerosis. Increased aortic stiffness has
emerged as a powerful predictor of survival in dialysis and can be measured
non invasively using pulse wave analysis technology (PWA). It is not clear
whether hemodialysis (HD) per se acutely affects endothelial function or
mechanical vessel wall properties as a result of the membrane bioincompat-
ibility or ultrafiltration. Aims: To analyse separately the effects on arterial
stiffness of membrane bioincompatibility and ultrafiltration during an HD
session.
Methods: PWA was obtained by applanation tonometry (SphygmoCor®).
Studied variables included: the augmentation index (AI), subendocardial
viability ratio (SEVR), ejection duration (ED), and aortic systolic and
diastolic blood pressure. Membrane bioincompatibility was detected by
successive white blood cell counts in the ADVIA autoanalyzer and C3a
generation (enzyme immunoassay Quidel).
a) Bioincompatibility effects analysis: leucocyte count, C3a levels and PWA
were monitored before, at 15, and at 30 minutes of HD session in 10 patients
using a cellulose diacetate membrane (Baxter). In order to avoid the effects
of intravascular volume changes on PWA, fluid removal was completely
avoided (ultrafiltration=0) during the 30 minuts of monitoring.
b) Ultrafiltration effects analysis: PWA was performed before and after a
conventional HD session with the same membrane in 19 patients (mean
ultrafiltration: 2,41±1,04 kg).
Results: a) A significant decrease in leucocyte count occurred at the begin-
ning of HD: 6801±1186 vs 4412±1333 at 15 minutes (p<0,001), while C3a
levels sharply increased from 427±269 to 3501±1638 ng/ml at 15 minutes
(p<0,000), being both parameters inversely correlated (r2 = 0,74, p=0,01).
No changes were demonstrated in any of the variables analysed in PWA:
AI (28±11 vs 29±15), ED (38±6 vs 36±5), SEVR (124±30 vs139±29).
Only aortic systolic BP was lower at 15 minutes: 118,5±16 vs 107,2±22
(p=0,009), in agreement with a reduction of brachial systolic BP: 154,7±24
vs 134,0±32 (p=0,01), without changes in aortic or brachial diastolic BP.
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b) In contrast, important changes in PWA were observed during the HD
session due to ultrafiltration: AI 31±11 vs 19±16, ED 37±4 vs 32±4,
SEVR 124±20 vs 171±36, central aortic systolic BP 139±25 vs 119±27
(all p<0,00), central aortic diastolic BP 75±13 vs 75±17 (p:ns).
Conclusions: HD with cellulose diacetate acutely induced a transient state
of inmunoactivation due to bioincompatibility, non detectable by PWA.
Ultrafiltration during HD session leads to important changes in PWA.
SaP260 AVERAGE SYSTOLIC BLOOD PRESSURE AND PULSE
PRESSURE IN 48-HOUR AMBULATORY BLOOD
PRESSURE MONITORING AND POSTDIALYSIS
N-TERMINAL proBNP LEVEL REFLECT LEFT
VENTRICULAR HYPERTROPHY IN STABLE
HEMODIALYSIS PATIENTS
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Introduction and Aims: Hypertension and left ventricular hypertrophy
(LVH) are risk factors for mortality in hemodialysis patients. We investigated
whether N-terminal pro-brain natriuretic peptide (NT-proBNP) and the
parameters of ambulatory blood pressure monitoring (ABPM) are associated
with cardiac abnormalities in hemodialysis (HD) patients.
Methods: We measured pre- and postdialysis NT-proBNP and 48h-ABPM
and performed echocardiography. The HD day was defined as the 24hr
period beginning at 1h after the start of HD, and the interdialytic day was
defined as the subsequent 24h. The study involved 68 stable HD patients:
35 males, 33 females; mean age 49.5±14.3 years; mean HD duration
53.1±44.9 months; 27 (39.7%) with diabetes mellitus (DM).
Results: Mean pre- and postdialysis NT-proBNP were 8832.4 (209.9 –
25786.0) and 10500.1 (226.8 – 34215.5) pg/ml, respectively. Patients with
LVH (n=42) had a higher average systolic blood pressure (SBP) and pulse
pressure (PP) on the HD day (151.9±19.8 vs. 130.3±23.1; 73.1±19.5
vs. 53.4±18.4 mmHg), the interdialytic day (153.2±14.7 vs. 141.6±23.5,
72.2±23.2 vs. 63.4±17.6 mmHg) and 48h (152.5±27.4 vs. 140.1±23.0
mmHg, 70.8±24.4 vs. 62.7±18.4 mmHg, respectively) than those without
LVH (p<0.05), and pre- (14231±10377.4 vs. 5490.0±4754.0 pg/ml) and
postdialysis (16218.5±11407.0 vs. 6960.2±5963.0 pg/ml, respectively) NT-
proBNP levels were also greater in patients with LVH (p<0.05). Simple
regression analysis, average SBP, PP on the HD day (r = 0.58, r = 0.31),
the interdialytic day (r = 0.56, r = 0.27), and 48 h (r = 0.59, r = 0.22),
and pre- and postdialysis NT-proBNP (r = 0.86, r = 0.84, respectively) was
significantly correlated with LVM index (p<0.05), and average SBP, PP
on the HD day (r = -0.304, r = -0.317), 48 h (r = -0.276, r = -0.379),
and pre- and postdialysis NT-proBNP (r = -0.255, r = -0.272, respectively)
inversely correlated with ejection fraction (EF). On multiple regression
analysis, average SBP on the HD day and postdialysis NT-proBNP were the
only variable linked to LVM index (R2=0.566, p=0.006), and postdialysis
NT-proBNP to EF (R2=0.204, p=0.012).
Conclusions: These results suggest that the absolute value of the average
SBP on the HD day and postdialysis NT-proBNP may predict LVH and
cardiac dysfunction in stable HD patients.
SaP261 ESTIMATED GLOMERULAR FILTRATION RATE
FORMULA AND RELATIONSHIP TO EARLY PATIENT
OUTCOME POST CARDIAC SURGERY
Wei Sim, Julie Keneally, George Mellotte. Department of Renal Medicine,
St James’s Hospital & Trinity College, University of Dublin, Dublin,
Ireland
Introduction and Aims: Pre-operative Kidney function is a powerful
predictor of operative mortality in patients undergoing coronary artery
bypass surgery. Modification of Diet in Renal Disease (MDRD) study
equation gives an estimated glomerular filtration rate (eGFR) adjusted
for body-surface area. The aim of this study was to explore relationship
between assessment of kidney function by the MDRD equation and patient
outcome.
Methods: The eGFR was calculated for a patients undergoing cardiothoracic
surgery over a 6 month period. The presence of additional risk factors,
hypertension and diabetes was recorded.
Results: Retrospective analysis of patient records regarding renal complica-
tions and outcome to discharge was available for all patients & at 6 weeks for
78% (n=264). The mean age was 65±11.8 years: (range 26-90). The Male
female ratio was almost 4:1. 43% had treated hypertension pre-surgery, 19%
had hypertension and diabetes and 6% had diabetes alone. Total Diabetes
(n=65) The mean serum creatinine was 104±.44umol/l. 25% (n=63) had
a raised serum creatinine. 1% (n=3) had a serum creatinine >200umol/l.
4%(n=12) had creatinine>150umol. The MDRD formula identified signif-
icantly higher incidence of renal dysfunction. Mean eGFR was 60±15.8
mls/min/1.72m2. 178 (59%) patients had an eGFR >60 mls/min/1.72m2 111
(37%) had an eGFR >30mls<60mls/min/1.72m2. 9 (3%) patients had more
severe renal failure, 1 of which was on dialysis pre surgery. For patients
with Diabetes, the corresponding incidence was 59%, 34% and 6.5%. For
hypertension, 51%, 43% and 5.5%.
There were 10 deaths at 6 weeks post surgery – overall mortality 3.3%. 3
patients with eGFR >60 mls/min/1.72m2 required dialysis post operatively
and 2 died (1.2%). 8 patients with eGFR >30mls<60mls/min/1.72m2
required dialysis, 4 died. & 4 other deaths in this group. Total (7.6%).
Nopatients with more severe renal failure died though 2 required dialysis
post operatively. 13 patients required dialysis post operatively (6 died –
46% mortality). 16 had a significant rise in creatinine >25%, 1 died.
Conclusions: There is a high prevalence of chronic kidney disease in patients
undergoing cardiothoracic surgery. Risk factors such as hypertension or
diabetes were not a strong predictor to the likelihood of renal disease.
Patients with pre-existing renal disease were at a higher risk of death and a
need for dialysis post surgery.
SaP262 THE DIFFERENCE OF CHANGE OF B TYPE
NATRIURETIC PEPTIDE (BNP) AND
N-TERMINAL-proBNP DURING HEMODIALYSIS
Hyun-Jung Kim, Kyung Jin Lee, Min Ok Kim, Young Sook Lee. Internal
Medicine, Eulji University, Daejeon, South Korea
Introduction and Aims: The most important cause of mortality in end-
stage renal disease (ESRD) patients receiving maintenance hemodialysis
(HD) is cardiovascular diseases, such as ischemic heart disease and conges-
tive heart failure (HF). The cardiovascular risk factors are lipoprotein(a),
inflammation, abnormal calcium/phosphate metabolism, uremic toxin and
volume overload. Blood measurements of B type natriuretic peptide (BNP)
and N-terminal-proBNP (NT-proBNP) have been used to identify patients
with HF and they are biochemical marker of cardiac mortality. BNP is
cleaved with NT-proBNP from pre-proBNP by ventricular myocyte stretch.
But, the elimination by dialysis of this two peptides are different. BNP is
easy eliminated by HD due to small sizes and short half-life.We evaluated
the difference of this two natriuretic peptides before and after HD and
the relationship with echocardiography. And we compared this relationship
according to left ventricular (LV) geometry.
Methods: We measured BNP, NT-proBNP and echocardiography before
and after HD in patients without HF who had been undergoing regular HD
for a period of at least 3 month at Eulji university hospital from March
1, 2004 to February 30, 2006 (n=34). Patients are divided to normal and
abnormal (concentric remodeling, eccentric LV hypertrophy and concentric
LV hypertrophy) group by LV geometry.
Results: The effect of HD on plasma concentrations of BNP and NT-
proBNP was different. BNP was significantly decreased after HD (preHD vs
postHD, 187.0±237.0 vs 138.5±187.5 pg/mL, p<0.001), and NT-proBNP
was significantly increased after HD (6258.7±7331.2 vs 8368.0±9352.0
pg/mL, p<0.001). BNP was related to left atrial volume index (LAVI)
at preHD (r=0.435, p=0.018) and postHD (r=0.503,.p=0.005). NT-pro
BNP was related to interventricular septum in diastole (IVSd) at preHD
(r=0.498, p=0.003) and postHD(r=0.453, p=0.007) and LV mass index
(LVMI) at preHD (r=0.413, p=0.019) and postHD (r=0.455, p=0.009).
But amount of ultrafiltration and Kt/V were not related to BNP and
NT-proBNP. Abnormal LV geometry group compared with normal group
was higher BNP (243.3±300.3 vs 120.0±97.8 pg/mL, p=0.126) and NT-
proBNP (9362.8±8479.2 vs 2787.8±3514.0 pg/mL. p=0.006). The changes
of BNP(postHD, abnormal vs normal group, 119.9±97.8 vs 99.1±88.1
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pg/mL), and NT-proBNP(12396.7±10517.5 vs 3835.8±5065.4 pg/mL)
during HD in both groups were same with previous results.
Conclusions: BNP and NT-proBNP were correlated with LV geometry and
NT-proBNP was superior than BNP in our HD patients. This is similar to the
results of cardiac patients with normal renal function. BNP was decreased
and NT-proBNP was increased during HD. The cause of increase in NT-
proBNP could be suggested to increased production during HD and late
elimination due to large molecular weight and long half-life of NT-proBNP
and characteristics of hemodialyzer. So, further study for the clearance of
natriuretic peptides according to different hemodialyzer and evaluation for
cause of increase of natriuretic peptide production and secretion during HD
session is necessary.
SaP263 SPATIAL QRS-T ANGLE IN PERITONEAL DIALYSIS
PATIENTS: ASSOCIATION WITH COMMON CAROTID
ARTERY INTIMA-MEDIA THICKNESS AND CORONARY
ARTERY CALCIFICATION
Andrzej Jaroszynski 1, Lucyna Janicka 1, Anna Drelich-Zbroja 2,
Elzbieta Czekajska 2, Andrzej Drop 2, Malgorzata Trojanowska 2,
Andrzej Wysokinski 3, Andrzej Ksiazek 1. 1Department of Nephrology,
Medical University of Lublin, Lublin, Poland; 2Department of Radiology,
Medical University of Lublin, Lublin, Poland; 3Department of Cardiology,
Medical University of Lublin, Lublin, Poland
Introduction and Aims: The spatial angle between the directions of
ventricular depolarization and repolarization (QRS-T angle), is a combined
measurement of the electrical activity of the heart and predicts cardiovascular
morbidity and mortality in various groups of patients.
We designed this study with 2 objectives: (1) to estimate the spatial QRS-T
angle in a group of selected peritoneal dialysis (PD) patients, and (2) to
assess the possible association between QRS-T angle and coronary artery
calcium burden, atherosclerosis, and some biochemical measurements.
Methods: The angular differences between the maximum spatial QRS and
T vectors were reconstructed from the digitally stored 12-lead ECG in 52
PD patients and in 65 controls. In PD patients coronary artery calcification
(CAC) score was performed by using multi-row computed tomography.
Atherosclerotic disease was assessed by measuring common carotid artery
(CCA) intima-media thickness (IMT) and plaque score (sum of maximum
thickness in millimeters of all plaques on both sides) by using an ultrasound
scanner.
Results: QRS-T angle values were more than twofold higher, in PD
patients compared with controls (31.42±12.88 and 13.05±7.87 respectively;
p<0.001).
Median CAC score equaled 16.1 Agatson units (range, 0 to 2478). No
calcification (CAC score < 10 Agatson units) was found in 26,3%. Agatson
score was > 400 units in 36,8% of patients. IMT was increased (>1.0 mm)
in 78.8%, and atherosclerotic plaques were detected in 84.6% of patients.
The plaque score was 7.57±5.49. In 32.7% of patients, troponin T values
were > 0.1 mmol/l.
QRS-T angle values were higher in patients with CAC score > 400
Agatson units compared with patients with CAC score < 400 Agatson units
(p=0.015). QRS-T angle values were also higher in patients with IMT > 2
mm compared with those with IMT < 2mm.
The Pearson test showed significant correlation between QRT-T angle and
HDL (r= - 0.322, p=0.015), troponine T (r= 0.359, p=0.006), CAC score (r=
0.418, p=0.001), and plaque score (r= 0.339, p=0.010). The relation between
QRS-T angle and hemoglobin was borderline (r= - 0.253, p=0.058).
Using multivariate analysis, either CAC score or troponine T level were
found to be independent predictors of QRS-T angle values.
Conclusions: The spatial QRS-T angle is high in PD patients and is mainly
associated with coronary artery calcium burden and troponin T elevation.
The possible clinical importance of the higher QRS-T angle in PD patients
remains to be confirmed in further studies.
SaP264 ULTRASOUND GUIDED COMPRESSION (USGC) ON
IATROGENIC FEMORAL PSEUDOANEURYSMUS (FPA)
IN HEMODIALYSED (HD) PATIENTS
Przemyslaw Wierzbicki 1, Monika Prokopiuk-Wierzbicka 1 ,
Miroslaw Dziekiewicz 2, Zofia Wankowicz 1. 1Department of Nephrology,
Military Institute of Medicine, Warsaw, Poland; 2Department of Vascular
Surgery, Military Institute of Medicine, Warsaw, Poland
Introduction and Aims: As the femoral artery cannulation (FAC) appeared
to be the most reliable access for diagnosis and therapy of cardiovascular
diseases in HD pts, the risk of FPA especially in aged pts with more
advanced atherosclerosis should be considered.
Methods: We assessed the occurrence of FPA as well as usefulness of
USGC as the first line conservative therapy of FPA in the group of 37
consecutive HD pts (23M, 14F, aged 55,5±8,2 years, on HD 24,2±22,6
mnths) who after FAC underwent regular femoral duplex USG (FdUSG).
Indications for FAC were as follows: cardiac angiography (31/37); coronary
angioplasty (4/37); renal artery angioplasty (2/37). Only 4 pts were on
systemic anticoagulation. FdUSG was performed immediately after release
the compression of artery after FAC.
Results: FPA was found in 9/37 (24%) pts, had size from 2,3 to 5,8cm
(mean 3,6cm) with size of neck of PA 1,3 to 3,0mm (mean 1,8mm), aged
12±8 hours after release of the FA compression.Our protocol of USGC
included vascular surgery standby, identification of PA channel to native
artery (it means neck of PA), then two consecutive 20min compression
intervals to obliterate blood flow with 9MHz probe and restudy after 24hrs.
USGC resulted in successful thrombosis in 5/9pts but failed in 4 other
patients, who required standard surgical operation. The failed group was
older (64±8 years) with more advanced atherosclerosis. The size of PA,
especially the neck of PA, as well as the age of PA was similar in both
groups of patients.
Conclusions: In conclusion, we recommend USGC as the first line conser-
vative therapy of FPA being in our material rather frequent complication of
FAC in HD pts.
SaP265 LOW CHOLESTEROL ALONG WITH HIGH
INFLAMMATION LEVEL PREDICT MORTALITY IN
HEMODIALYSIS PATIENTS
George Tsirpanlis 1, George Triantafyllis 1, Alexandra Fatourou 1,
Eleni Sakka 1, Fotini Boufidou 2, Margarita Zoga 2, Kyriaki Stamatelou 3,
Aliki Bleta 4, Stylianos Chatzipagiotou 2 , Chrysoula Nicolaou 2.
1Nephrology, General Hospital of Athens, Athens, Greece; 2Medical
Biopathology, Eginition Hospital, Medical School, University of Athens,
Athens, Greece; 3Renal Unit, Blue Cross Hospital, Athens, Greece; 4Renal
Unit, Dragini Clinic, Athens, Greece
Introduction and Aims: An inverse association between total serum choles-
terol (TChol) and mortality has been observed in hemodialysis (HD) patients.
The verification of this “reverse epidemiology” as well as the potential role
that inflammation concomitantly plays in this phenomenon is being explored
in the present study.
Methods: A group of 136 stable HD patients was prospectively followed and
cardiovascular disease (CVD) as well as all-cause mortality was recorded
for a time period of 24 months. Baseline characteristics, lipid profile and
inflammatory indexes were investigated as potential survival predictors.
Results: During follow-up 21 deaths (11 due to CVD), 9 renal transplan-
tations and 5 loses to follow-up occurred. In univariate Cox regression
survival analysis, decreasing TChol, increasing C-reactive protein (CRP),
Interleukin-6 (IL-6) and IL-6 x soluble IL-6 receptor/soluble gp130 ratio
were common predictors for both CVD and all cause mortality. Decreasing
body mass index and decreasing interleukin-10 (IL-10) level were addi-
tional predictors for CVD mortality. In multivariate Cox regression analysis,
decreasing TChol was the common significant predictor for CVD (RR 0.98,
95% CI 0.96-1.00, p = 0.03, mean±SD TChol 167.4±47.9 in survivors
vs. 122.0±26.5 mg/dl in non-survivors) and all cause mortality (RR 0.98,
95% CI 0.97-0.99, p = 0.04), while increasing IL-6 and decreasing IL-10
were additional predictors for CVD (RR 7.14, p = 0.05 and RR 0.97, p
= 0.05 respectively, mean±SD IL-6 9.5±8.9 in survivors vs. 18.2±15.9
pg/ml in non-survivors and IL-10 11.3±21.5 in survivors vs. 5.5±4.6 pg/ml
in non-survivors) and increasing CRP for all-cause mortality (RR 6.28, p
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= 0.001, mean±SD CRP 9.4±11.6 in survivors vs. 23.1±18.8 mg/ml in
non-survivors).
Conclusions: Increased pro-inflammatory and decreased anti-inflammatory
activity in concert with low cholesterol seems to influence survival in HD
patients. Thus, it seems that reverse epidemiology applies in the case of
low cholesterol levels, though it could be largely explained by the increased
inflammatory activity observed in this population.
SaP266 THE INFLUENCE OF SPIRONOLACTONE ON PLASMA
LEVEL OF PLASMINOGEN-ACTIVATOR INHIBITOR TYPE
1 (PAI-1) IN ANURIC HEMODYALISIS PATIENTS
Ashot Essaian 1, Ivan Kaukov 1, Aygul Karabayeva 1,
Margarita Kadinskaya 2, N. Katysheva 2. 1Nephrology and Dialysis
Department, Saint Petersburg Pavlov’s Medical University, Saint
Petersburg, Russian Federation; 2Department of Clinical Laboratory
Diagnostics, Saint Petersburg Pavlov’s Medical University, Saint
Petersburg, Russian Federation
Introduction and Aims: It was established that aldosterone mediates
fibrosis, collagen formation and target organ dysfunction particularly by
induction of vascular smooth muscle cell hypertrophy, and endothelial
dysfunction. Such effect of aldosterone is realized mainly by the modulation
of PAI-1 expression.
The aim of our study was to assess the effect of aldosterone receptor
blockade by spironolactone on plasma PAI-1 level in anuric hemodyalisis
patients.
Methods: 83 anuric hemodyalisis patients (mean age – 50,74±9,44 years)
have been studied, dividing in 2 groups. Group 1 patients (n= 42) received
usual therapy, group 2 (n=41), in addition to standard therapy, received
spironolactone (25 mg per day) during the 6 months. PAI-1 activity levels
were measured using an assay with standardized commercial kits (Biopool
Inc.), with results expressed as units per milliliter.
Results: The basal levels of PAI-1 in group 1 and group 2 were 6,1±0,11
U/ml and 5,2±0,05 U/ml, respectively (the upper limit of normal is 3,5
U/ml). After 6 months of follow up the level of PAI-1 in group 1 decreased
significantly (3,1±0,11 U/ml, p < 0,0001). In group 2 mean PAI-1 level
remained unchanged (p>0.05).
No patients developed hyperkalemia during the spironolactone treatment
period.
Conclusions: (1) Blocade of aldosterone receptors by spironolactone in
hemodialysis anuric patients reduses PAI-1 level, thus, preventing endothe-
lial dysfunction and vascular smooth muscle cell hypertrophy.
(2) In such patients long-term (6 months) treatment with spironolactone in
low doses does not induce hyperkalemia.
SaP267 VITAMIN E-COATED CELLULOSE ACETATE DIALYSIS
MEMBRANE: LONG TERM EFFECT ON INFLAMMATION
AND OXIDATIVE STRESS
Dimitrios Hadjiyannacos 1, Polixeni Metaxaki 1, Vassilios Sideris 2,
Angeliki Anogiati 2 , Dimosthenis Vlassopoulos 1. 1Nephrology, A. Fleming
Hospital, Athens, Greece; 2Hematology, Pendeli Pediatric Hospital, Athens,
Greece
Introduction and Aims: Chronic inflammation and oxidative stress associ-
ation is prevalent in patients undergoing hemodialysis (HD). Vitamin E is
a fat-soluble antioxidant that reduces lipid peroxidation and the generation
of reactive oxygen species. Our aim was to investigate the influence of
a vitamin E-coated cellulose acetate (CAE) membrane on oxidative and
inflammation biomarkers.
Methods: Nine stable HD patients (median age: 66 years, range: 50-71;
median HD duration: 52 months, range: 8-142) dialyzed 3 times a week
with polysulfone (PS) low flux membrane, for 12 hours/week (9-15), were
switched to CAE membrane for 3 months and then changed back to PS
membrane again for 6 months. Diabetics, patients on ACE inhibitors, statins,
corticosteroids or with evidence of inflammatory disease were excluded.
Oxidative stress biomarkers measured were: Reactive oxygen metabolites
and derivatives (d-ROMs) (d-ROMs Test™-FRAS 4, Grosseto, Italy) and
total anti-oxidant capacity (TAC) by spectrophotometry, and superoxide
dismutase (SOD) by ELISA. Inflammation biomarkers measured were:
High sensitivity CRP (Hs-CRP), IL-6 and TNF-a by ELISA. Blood samples
were taken, before dialysis session, at baseline, 3 (end of use of CAE)
and 9 months after, then centrifuged and frozen at –70°C. All patients
underwent HD with low molecular weight heparins and received rHuEpo,
iron, carnitine and folic acid. During the study all dialysis parameters, except
membranes, were kept unchanged. Non-parametric tests were applied for
statistical analysis.
Results: The results are reported in the Table 1: Oxidative stress biomarker
d-ROMs lowered significantly 6 months after CAE treatment. TAC rose,
also significantly, by the same time while SOD increased rapidly and
immediately after the end of CAE treatment. Inflammation markers Hs-
CRP, TNF-a and IL-6 were significantly lowered, late, at 6 months after
CAE treatment.
Table 1: Changes of inflammation and oxidative stress biomarkers
Baseline 3 months 9 months P
Hs-CRP (μg/ml) 15.9±8.7* 13.6±9.3 2.9±1.9* *<0.03
IL-6 (pg/ml) 12.6±7.6* 11.0±10.1 5.8±4.3* *<0.02
TNF-a (pg/ml) 15.5±6.6 23.9±23.4* 9.3±8.4* *<0.04
d-ROMs (Units) 321.7±48* 338.4±99.4 288.2±63.7* *<0.03
TAC (mmol/l) 1.3±0.3* 1.4±0.3 1.5±0.3* *<0.02
SOD (U/ml) 9.2±6.6* 14.3±8.3* 13.4±6.8 *<0.009
Conclusions: Vitamin E-coated cellulose acetate dialysis membrane leads
to an increase in anti-oxidant serum activity, as evidenced by SOD,
immediately, and on the long-term by TAC rise and d-ROMs decrease. This
was associated with a delayed effect on inflammation indices as evidenced
by Hs-CRP, TNF-a and IL-6 lowering by the end of the study.
SaP268 CARDIOVASCULAR OUTCOME IN ASYMPTOMATIC
HAEMODIALYSIS PATIENTS SUBMITTED TO
AGGRESSIVE MEDICAL THERAPHY: A 30-MONTH
FOLLOW UP
Maurizio Lonzi 1, Simone Manca di Villahermosa 1, Francesco Summaria 2,
Michela Tedesco 1, Giovanni Colarieti 1, Antonio Favarò 1, Gebran
M. Chamoun 1, Orazio Schillaci 3, Roberta Danieli 3, Massimo
Taccone Gallucci 1. 1Nephrology, Tor Vergata University, Rome, RM, Italy;
2Cardiology, Policlinico Casilino ASL RMB, Rome, RM, Italy; 3Nuclear
Medicine, Tor Vergata University, Rome, RM, Italy
Introduction and Aims: During May and June 2004 a baseline 99mTc
sestamibi stress myocardial perfusion scintigraphy (SPECT) was performed
in thirty-one asymptomatic HD patients with no history of cardiovascular
disease (CVD) nor clinical, electrocardiographic or ultrasonographic signs
of myocardial ischemia. Silent myocardial ischemia (SMI) consisting in
significant reduction of myocardial perfusion under stress in otherwise
asymptomatic subjects was reported in 18 of 31 patients (58.1%) (Tedesco
M, NDT 2005, 20s6). All patients underwent aggressive medical therapy
for primary prevention of major adverse cardiac events (MACEs). Here
we investigated the cardiovascular outcome of these patients during a
thirty-month follow up.
Methods: Both patients with and without SMI at SPECT (SPECT+ and
SPECT-, respectively) received an aggressive medical regimen consisting in
Pravastatin 40mg daily regardless serum LDL cholesterol, antiplatelet drugs,
hypotensive medications associated to ACE-I and/or ARBs to maintain
blood pressure below 130/80mmHg, insulin and/or glucose lowering drugs
to keep baseline blood glucose between 80 and 120mg/dL and glycosilated
hemoglobin below 7% in diabetic patients, Sevelamer and calcium carbonate
to keep serum phosphate below 5.5mg/dL, calcitriol to keep serum i-PTH
between 150 and 300ng/mL.
Results: A total of six patients died during the follow up, four among
SPECT+ (22.2%) and two among SPECT- patients (15.4%); causes of
death were acute myocardial infarction, rupture of abdominal aneurysm
and neoplastic disease (2) in SPECT+ patients; stroke and intestinal
infarction in SPECT- patients. Coronary arteriography was performed in
five SPECT+ patients; subsequent successful PTCA was necessary in two.
Among SPECT- patients two developed unstable angina and underwent
coronary arteriography and subsequent successful PTCA, three received
kidney transplantation. In both groups no drop out was observed due to
intolerance to the prescribed medications.
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Conclusions: After a 30-month follow up under aggressive medical therapy
cardiovascular outcome of the patients of the two groups, who as previously
reported showed no significant differences in conventional and emerging
cardiovascular risk factors (Manca di Villahermosa S, NDT 2006, 21s7), is
comparable regardless the presence or absence of SMI. Hence, as CVD is
by far the first cause of death in ESRD, an aggressive medical management
may be highly advisable for the primary prevention of MACEs in all HD
patients.
SaP269 THE PENTRAXINS C-REACTIVE PROTEIN (CRP) AND
PENTRAXIN 3 (PTX3) AUGMENT CALCIFICATION OF
HUMAN VASCULAR SMOOTH MUSCLE CELLS (SMC)
Daniel Zickler, Petra Koehne, Olaf Boenisch, Natalie Otto, Ralf Schindler.
Department of Nephrology and Intensive Care Medicine, Campus
Virchow-Klinikum, Charite Universitaetsmedizin Berlin, Berlin, Germany
Introduction and Aims: Cardiovascular mortality is greatly increased in
patients suffering from end stage renal disease (ESRD). Both proteins are
elevated in plasma of patients with chronic inflammatory conditions such
as ESRD and plasma levels of CRP and PTX3 are associated with future
cardiovascular events. In addition, CRP as well as PTX3 are markedly
expressed in atherosclerotic plaques. Whether pentraxins play a causal
role in the pathogenesis of atherosclerosis is controversially discussed.
We investigated whether recombinant, endotoxin-free CRP and PTX3 have
direct effects on calcification of SMC in vitro. In addition, cytokine induction
in PBMC by pentraxins was also investigated.
Methods: Human SMC were isolated from umbilical veins, cultured and
used for experiments in their 4th passage. Confluent cells were incubated
for 48h with a calcification-inducing medium (2 mM Calcium and 2
mM phosphate) containing either PTX3, CRP (both R&D systems) or
endotoxin (L55:B5, Sigma). After incubation, intracellular calcium content
was determined via the o-cresolphthalein-complex method (Wako) and
the von Kossa method. Expression of the calcification inhibitor Matrix
G protein (MGP Ia) was investigated via RT-PCR. Furthermore, PBMC
of healthy individuals were isolated and incubated with CRP, PTX3 or
endotoxin for 24 hours. Induction of interleukins IL-1, IL-6 and TNF
alpha was determined by ELISA. Endotoxin was measured by chromogenic
Limulus-test (BioWhittaker, sensitivity 0.03 U/ml).
Results: After incubation with CRP or PTX3 SMC incorporated signif-
icantly greater amounts of calcium compared to controls (table). Similar
findings were observed microscopically using the von Kossa stain. mRNA
expression of MGP Ia in SMC decreased after incubation with CRP. In
PBMC PTX3 and CRP dose-dependently induced production of all studied
cytokines. The concentration of endotoxin in CRP and PTX preparations
were always below the threshold for cytokine induction.
Conclusions: The pentraxins PTX and CRP augment calcification of SMC
in vitro. This effect appears not to be related to endotoxin contamination.
The clinical association between cardiovascular risk and pentraxin plasma
concentration might reflect activation of PBMC and augmentation of
calcification in SMC by pentraxins that appear as possible mediators in
the pathogenesis of atherosclerosis. Our results support the link between
inflammation and atherosclerosis.
SaP270 RISK FACTORS FOR CALCIFICATION AND MORTALITY
IN UREMIA: RESULTS FROM THE BASCH STUDY
Georg Schlieper 1, Vincent Brandenburg 1, Zivka Djuric 2,
Tatjana Damjanovic 2, Ralf Westenfeld 1, Jürgen Floege 1,
Markus Ketteler 1, Nada Dimkovic 2. 1Nephrology and Clinical
Immunology, RWTH University Hospital, Aachen, Germany; 2Center for
Renal Diseases, Zvezdara University Hospital, Belgrade, Serbia
Introduction and Aims: Patients with chronic kidney disease have a drasti-
cally increased cardiovascular mortality. Risk factors contributing to uremic
vascular calcification include chronic inflammation, hyperphosphatemia,
and an increased calcium x phosphate product. Recently, we established a
simple calcification score to assess the degree of cardiovascular calcifica-
tion in hemodialysis patients in the BASCH (Belgrade Aachen Study on
Calcification in Hemodialysis patients) study.
Methods: In the BASCH study we included 97 patients (55±9 years).
Patients were enrolled between December 2003 and January 2005 and
observed for 18-26 months. Calcification was assessed using the Adragao
score (X-rays of pelvis and hands; NDT 19:1480, 2004) and a composite
calcification score (Adragao score plus X-ray of AV-fistula plus ultrasound of
carotid arteries, mitral and aortic heart valves). Tertiles of both calcification
scores were used to perform a survival analysis (Kaplan-Meier).
Results: In the multivariate analysis diabetes (p=0.04), male gender
(p=0.001) and phosphate (p=0.04). were independent predictors of calcifi-
cation. Diabetes was the only clinical risk factor for mortality (p=0.0003)
while other risk factors like serum calcium, phosphate, ultrasensitive CRP,
fetuin-A or osteoprotegerin were not associated with mortality. The tertile
with lowest calcifications in the composite calcification score but not the
Adragao score was associated with a better survival (p=0.037).
Conclusions: In our study, diabetes and cardiovascular calcifications were
the most important risk factors for mortality. The novel composite calcifica-
tion score is a cost-effective method to assess cardiovascular risk.
SaP271 CAROTID-INTIMA MEDIA THICKNESS AND
ENDOTHELIAL FUNCTION RELATIONSHIP IN
PERITONEAL DIALYSIS PATIENTS
Huseyin Kocak 1, Erkan Mahsereci 1, Cengiz Ermis 2, Kaan Ceken 3,
Gultekin Suleymanlar 1, Fevzi Ersoy 1, Gulsen Yakupoglu 1 , Murat Tuncer 1.
1Nephrology, Akdeniz University Schooll of Medicine, Antalya, Turkey;
2Cardiology, Akdeniz University Schooll of Medicine, Antalya, Turkey;
3Radiodiognostic, Akdeniz University Schooll of Medicine, Antalya, Turkey
Introduction and Aims: Detection of atherosclerosis in the early stage
is one of the important tool for the planning of future treatment. It
has been well known that there is an increased carotid intima media
thickness (CIMT) and existence of endothelial dysfunction (ED) in the
early stage of atherosclerozis, both of which are also risk factors for future
coronary events.It has been shown that peritoneal dialysis (pd)patients are
characterized by increased CIMT and ED. In this study, we investigated
whether there is a relation between CIMT and endothelial function in PD
patients.
Methods: We included 54 PD (female/male: 28/26, mean age: 42±11)
patients who were not characterized by diabetes mellitus, atherosclerotic
disease, presence of active infection and history of peritonitis in the last
three months and age and gender matched 30 controls (female/male: 16/14,
age: 43±10). After demographic data was recorded, 24 hr ambulatory
blood pressure and biochemical parameters were measured in each subject.
Morever; CIMT and endothelial function of each subject were measured by
non-invasive tecnique described by elsewhere.
Results: CIMT were higher in PD patients than in controls (0.84±0.08 mm
vs 0.75±0.06 mm, P<0.01). It was also found that flow mediated dilatation
% (FMD %) were lower in PD patients than those of controls (8.2±5.0% vs.
11.7±5.5% P<0.01). In addition; nitrate mediated dilatation % (NMD %)
were also lower in PD patients than in controls (18.1±8.5% vs. 26.4±4.6%,
P<0.01). Correlation analysis showed that there was no relation between
CIMT and FMD % (r=-0.004, p=0.94).
Conclusions: PD patients were characterized by increased CIMT and
endothelial dysfunction expressed as low FMD %. No existence of relation
between CIMT and endothelial function in our PD patients may show that
these modalities indicate different stage of atherosclerosis.
vi324 Cardiovascular complications of CKD 2 Saturday, June 23, 2007
SaP272 DETERMINANTS OF CORONARY ARTERY
CALCIFICATION PROGRESSION IN PATIENTS WITH
CHRONIC KIDNEY DISEASE NOT ON DIALYSIS
Domenico Russo 1, Salvatore Corrao 2, Ida Miranda 1, Carolina Ruocco 1,
Elisa Buonanno 1 , Yuri Battaglia 1, Diego Brancaccio 3, Mario Cozzolino 3,
Vittorio E. Andreucci 1. (1)Department of Nephrology, University of Naples
“Federico II”, Naples, Italy; 2Laboratory of Clinical Epidemiology,and
Biostatistics, University of Palermo, Palermo, Italy; 3Renal Division, S.
Paolo Hospital. University of Milan, Milan, Italy
Introduction and Aims: Vascular calcifications (VC) are predictors of
morbidity and mortality in patients on dialysis (ESRD-patients). VC and
particularly coronary artery calcification (CAC) proceed over time. Ab-
normal mineral metabolism as well as reduction of “protective” proteins
(e.g. fetuin-A) are involved in progression of CAC. Rapid progression
is regarded as additional factor responsible for morbidity and mortality.
Determinants of CAC progression have not been evaluated in patients with
kidney disease not undergoing dialysis (CKD-patients). This study assesses
CAC progression and determinants in CKD-patients. Awareness of rate and
potential determinants of CAC can allow early therapeutic interventions and
expectantly hinder cardiovascular morbidity and mortality.
Methods: Consecutive out-patients (age 18-70 years) with normal or
reduced renal function (stage 3-5 CKD not on dialysis) were enrolled. Ex-
clusion criteria were: symptomatic coronary disease; arrhythmia; myocardial
infarction; diabetes. In patients with diabetes CAC progression is greater
and independent of mineral metabolism and renal function. Serum cal-
cium, phosphorus, parathyroid hormone, homocysteine, C-reactive protein,
triglycerides, total cholesterol, high- and low-density lipoprotein cholesterol
were serially measured. Fetuin-A was assessed at the entry and at the end
of the study. CAC progression was detected by measuring total calcium
score (TCS) with computed tomography. Follow-up lasted 24±4.2 months
(mean±SE).
Results: n.53 patients had CKD and 60 had normal renal function (NRF-
patients). Patients with CAC were older with lower fetuin-A. TCS increased
from 73±17 to 80±20 (mean±SE; p=NS) in NRF-patients and from
384±116 to 602±140 (mean±SE; p<0.01) in CKD-patients. Despite the
majority of patients had normal concentration, phosphorus [O.R.=1.97
(1.14-3.41, 95% C.I.); p=0.015] correlated with CAC progression. N.11
CKD-patients, 45-70 years old, experienced fatal or not fatal cardiovascular
event. All but one patient presented progression of CAC. In contrast, no
event occurred in NRF-patients.
Conclusions: CAC progression was prominent in CKD-patients and cor-
related with serum phosphorus. Cardiovascular events were more frequent
in CKD-patients. Studies are required to ascertain whether the attainment
of serum phosphorus lower than that suggested by guidelines may reduce
CAC progression, and ultimately mortality.
SaP273 LOW DENSITY LIPOPROTEIN (LDL) APHERESIS FOR
HEMODIALYSIS PATIENTS WITH PERIPHERAL
ARTERIAL DISEASE (PAD) REDUCES REACTIVE
OXYGEN SPICES (ROS) PRODUCTION VIA
SUPPRESSION OF NADPH OXIDASE GENE IN
LEUKOCYTE
Taiga Hara 1, Hideyasu Kiyomoto 1 , Hirofumi Hitomi 1, Kumiko
Moriwaki 1, Genei Ihara 1, Kumiko Kaifu 1, Chihiro Kurozumi 1, Tadashi
Sofue 1, Yoshiko Fujita 1, Toyomu Ugawa 1, Chikako Higashiyama 1,
Masakazu Kohno 1, Akira Nishiyama 2. 1Division of Nephrology and
Dialysis, Dept. of CardioRenal and CerebroVasular Medicine; 2Dept. of
Pharmacology, Faculty of Medicine, Kagawa University, Kagawa, Japan
Introduction and Aims: Peripheral arterial disease (PAD) is the major
complication in hemodialysis (HD), especially with diabetes mellitus.
Previous reports indicated that the Low density lipoprotein (LDL) apheresis
improves arteriosclerosis in PAD patients; however, mechanism of LDL
apheresis for PAD is still not clear. In this study, we hypothesized that
LDL apheresis attenuates reactive oxygen species (ROS) production in HD
patients with PAD.
Methods: Twenty HD patients who have ischemic symptoms due to PAD
were investigated in present study. All subjects agreed with a protocol
named EDDEN (Effective drugs and/or dialysis evaluated NADPH oxi-
dase) study that was approved by medical ethics committee of faculty
medicine, Kagawa University (# H15-12). Informed consent was obtained
from all subjects before LDL apheresis was performed. The symptoms of
PAD were assessed by Fountain classification. The clinical effects were
evaluated by thermography and angiography. Blood samples were obtained
before and after LDL apheresis. We measured the serum levels of LDL
cholesterol, high density lipoprotein (HDL) cholesterol, malondialdehyde-
modified LDL (MDA-LDL), high sensitive C reactive protein (HSCRP),
bradykinin, fibrinogen, international normalized ratio of pro-thrombin time
(PT-INR), vascular endothelial growth factor (VEGF) and transforming
growth factor-beta (TGF-b). Oxidative stress in serum was evaluated by
TBARS (thiobarbituric acid reactive substances) and mRNA of leukocyte
was separated by PAXgene Blood RNA kit (PreAnalytiX Company, Switzer-
land). Gene expression of mRNA in leukocyte was measured by real time
PCR method.
Results: The ischemic symptoms due to PAD were gradually improved in
13 patients (65%) after starting LDL aphersis. One session of LDL apheresis
removed approximately 75% of LDL from the serum. Some patients showed
dramatically improvement of severe PAD symptoms such as ulcer of skin
after a serial of LDL apheresis. LDL cholesterol, MDA-LDL, HSCRP,
VEGF PT-INR and bradykinin were decreased between before and after
single session of LDL apheresis. However, there were no changes between
before and after 10 times LDL apheresis. The levels of fibrinogen and
p22phox mRNA were decreased in single session of LDL apheresis and the
effects on them were prolonged during whole observation periods. More
than 50% of down-regulation of p22phox mRNA expression in leukocytes
was observed after 10 times apheresis.
Conclusions: LDL apheresis improved the ischemic symptoms in HD
patients with PAD via the reduction of ROS production with the suppression
of NADPH oxidase gene expression in leukocyte. We conclude that LDL
apheresis is good therapy for HD patients complicated with PAD.
SaP274 IMPEDANCE CARDIOGRAPHY A NON-INVASIVE
METHOD FOR HEMODYNAMIC MONITORING OF
HAEMODIALYSED PATIENTS
Cristina Vaduva 1, Daniela Cana-Ruiu 2, Despina Toader 3,
Rodica Musetescu 3, Natalia Istrate 1, Corina Grauntanu 2, Mary Dragan 2,
Eugen Mota 2. 1Hemodialysis Center, County Emergency Hospital,
Craiova, Dolj, Romania; 2Nephrology Clinic, County Emergency Hospital,
Craiova, Dolj, Romania; 3Cardiology Center, County Emergency Hospital,
Craiova, Dolj, Romania
Introduction and Aims: Impedance cardiography (ICG) represents a non
invasive method for hemodynamic assessment and fluid status measurement
in haemodialysed patients.
Hemodynamic monitoring of haemodialysed patients using impedance
cardiography.
Methods: We included in the study 20 chronic haemodialysed patients
(12 male and 8 female) with the age range 28 to 68 (mean 53,2±11,48)
years.Using ICG, we studied the following parameters: blood pressure (BP),
cardiac index(CI), heart rate(HR), ejection fraction (EF), systemic vascular
resistance index (SVRI), thoracic fluid content (TFC. This parameters were
recorded pre and after haemodialysis (HD) session and the changes of
each parameters during HD were correlated with amount of fluid removed.
All patients underwent a adequate haemodialysis kt/v ≥ 1.2.For patients
had uncontrolled hypertension, 10 patients had normal values of BP and
6 patients had hypotension. Mean arterial pressure of the patients was
130±27,22 mmHg.
Results: TFC decreased in all patients during HD session (average reduction
0,012±0,008 ohms (-1)), and it was significant correlated with amount
of fluid removed. The amount of ultrafiltration was 2.45±0,46 L. Others
hemodynamic parameters were insignificantly correlated with fluid removed.
EF increased in all patients after HD but significantly only in hypotensive
patients. SVRI decreased after HD only in hypotensive patients.The patients
with hypertension and normal BP had an increased values of SVRI during
HD.
Conclusions: ICG represents an accessible and useful method for hemo-
dynamic monitoring in haemodialysed patients. Optimising hemodynamic
control we can improve heart failure management and subsequent decreased
of cardiovascular risk.
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SaP275 LEFT ATRIAL VOLUME IS A RELEVANT PREDICTOR OF
CARDIOVASCULAR OUTCOMES IN DIALYSIS PATIENTS
Giovanni Tripepi 1, Francesco A. Benedetto 2, Francesca Mallamaci 1,
Rocco Tripepi 1, Lorenzo S. Malatino 3, Carmine Zoccali 1. 1CNR-IBIM,
Clin. Epid. and Physiopath. of Renal Dis. and Hyp., Reggio Cal., Italy;
2Riuniti Hospital, Cardiol. Unit, Reggio Cal., Italy; 3Dpt. of Int. Med.,
Catania University, Catania, Italy
Introduction and Aims: Left atrial volume (LAV) is an important com-
ponent of heart geometry but the potential prognostic relevance of this
echocardiographic parameter in end stage renal disease (ESRD) patients is
still unexplored. In this prospective cohort study we have therefore tested
the prognostic value for CV events of single and repeated measurements of
LAV.
Methods: Two hundred and forty nine dialysis patients were enrolled into
the study and 191 of these (age: 59±15 yrs; 110 M and 81 F) repeated
echocardiography after an average interval of 17±2 months. LAV was
measured by the disk method (Lester SJ et al, Am J Cardiol 1999), i.e. a
method showing a satisfactory day to day reproducibility.
Results: LAV (height2.7 indexed) was significantly higher in dialysis
patients than in healthy subjects (P<0.001). During the follow-up, 113
patients died. LAV had an independent prognostic power for all cause
mortality in a multivariate Cox model [hazard ratio (1 ml/height2.7 increase
in LAV): 1.07, 95% CI: 1.03-1.12, P<0.001] adjusting for Framingham
risk factors (age, sex, smoking, diabetes, blood pressure and previous
CV events) and non traditional risk factors as well (albumin, CRP and
treatment modality). Furthermore, LAV maintained a significant predictive
value for death (P=0.03) also when LV mass and LV systolic function were
jointly introduced into the Cox’s model. Between the first and the second
echocardiographic study LAV rose from 10.5±5.0 ml/height2.7 to 11.6±5.6
ml/height2.7 (P<0.001). After the second study, 85 patients had fatal and
non fatal CV events. The rate of increase in LAV was significantly higher
(P<0.001) in patients with incident fatal and non fatal CV events (median
0.59 ml/height2.7/yr, inter-quartile range: 0.00-2.62 ml/height2.7 /yr) than in
events free patients (0.11 ml/height2.7 /yr, -0.27-0.58 ml/height2.7/yr). In a
multiple Cox regression model taking into account a series of potential
confounders including baseline LAV and LV geometry a 1 ml/m2.7/yr
increase in LAV was associated with a 12% increase in the relative risk of
fatal and non fatal CV events. The association between changes in LAV and
CV outcomes remained substantially unmodified [hazard ratio (1 ml/m2.7/yr
increase in LAV): 1.13, 95% CI: 1.06-1.21, P<0.001] also after the inclusion
of LV mass.
Conclusions: In patients with ESRD, a single measurement of LAV added a
significant prediction power to a Cox model including LV mass and function.
Furthermore, changes in LAV showed an independent prognostic value for
CV events beyond and above that provided by a single measurement. Left
atrial volume measurements provide prognostic information beyond that
given by LVH and LV ejection fraction and repeated echocardiographic
studies of left atrium are useful for CV risk monitoring in dialysis patients.
SaP276 MONOCYTE EXPRESSION OF ADHESION MOLECULES
DURING LOW AND HIGH FLUX POLYSULPHONE
HAEMODIALYSIS AND THE EFFECTS OF
ATORVASTATIN ADMINISTRATION
Aristeidis Stavroulopoulos 1 , Dimitris Petras 1, Ioannis Kakavas 1,
Kyriaki Stamatelou 2, Georgios Vissoulis 3, Vasilios Agroyannis 3, Ioannis
T. Papadakis 1. 1Nephrology Department, Hippokration General Hospital,
Athens, Greece; 2Renal Unit, Kyanous Stavros, Athens, Greece; 3Medical
School, University of Athens, Athens, Greece
Introduction and Aims: It has been suggested that inflammation is im-
plicated in the pathogenesis of cardiovascular disease and involved in
haemodialysis-related morbidity. We report part of the results of an ongoing
crossover study aiming to identify alterations in several inflammatory mark-
ers in patients on low (LFD) or high flux (HFD) polysulphone haemodialysis
and the influence of statin use.
Methods: We studied CD11b, CD18 and CD62L expression on monocytes
in 32 patients, 16 on LFD and 16 on HFD polysulphone haemodialysis,
before and after dialysis and also after administration of atorvastatin
20 mg/day for 6 months. The two groups were matched for age, sex,
duration of dialysis, with same prevalence of diabetes, and dialyzed with
an spKT/V≥ 1.3. 16 healthy blood donors were used as controls (C).
Monocytes were identified and analysed by flow cytometry after incubation
of blood with monoclonal antibodies against CD11b, CD18 and CD62L.
Antigen expression was defined as mean fluorescence intensity (MFI).
Results: Baseline pre-dialysis expression of CD11b and CD62L on mono-
cytes was significantly lower in dialysis patients compared to that in healthy
controls (P= 0.05 and P= 0.03 respectively), whilst no difference was found
for CD18. There was no statistically significant difference of baseline ex-
pression of all three molecules between LFD and HFD dialysis groups. After
dialysis there was an increase in the expression of CD11b and CD18 com-
pared to pre-dialysis baseline values (P< 0.001 and P= 0.03 respectively),
but expression of CD62L remained unchanged. No statistically significant
differences were found in post-dialysis expression and in the change () pre
and post-dialysis, of all three examined molecules, between the two dialysis
groups. After 6 months of treatment with atorvastatin there was a decrease
in pre-dialysis monocyte expression of CD11b and CD18 and an increase
in the expression of CD62L compared to pre-dialysis baseline values (P=
0.004, P= 0.05 and P= 0.001 respectively). Again there were no statistically
significant differences in after atorvastatin treatment pre-dialysis expression
and in the  before and after treatment, in all three molecules, between
patients on LFD and HFD haemodialysis (table).
MFI Pre-dialysis (MFI) Post-dialysis (MFI) After statin (MFI)
C LFD HFD LFD HFD LFD HFD
CD11b 17.1±4.3 14.5±5.6 14.4±4.9 22.2±10 24.4±9.5 11.3±6 11.5±4.8
CD18 17±2.5 17.3±3.9 17.7±2.4 19.6±4.2 18.9±2.7 14.6±4.1 16.4±5.1
CD62L 4.5±1.2 4.02±2 3.1±1.5 3.8±2.5 2.9±1.7 4.8±1.9 4.8±1.9
Conclusions: Patients on haemodialysis seem to have phenotypic alter-
ations in the expression of adhesion molecules on monocytes, which are
further influenced by the process of dialysis itself, irrespectively of the
membrane flux. Atorvastatin use induces changes in the expression of these
inflammatory mediators. Further studies are needed to evaluate the role of
inflammation and the clinical impact of statin use in dialysis patients.
SaP277 VASCULAR CALCIFICATION AND BONE DISEASE IN
HEMODIALYSIS PATIENTS ASSESSMENT,
ASSOCIATION AND RISK FACTORS
Delia Timofte, Dorin Ionescu, Lacramioara Medrihan, Adina Mandita,
Anca Rasina, Luminita Damian. Nephrology&Dialysis, University &
Emergency Hospital, Bucharest, Romania
Introduction and Aims: Vascular calcification and bone disease are com-
monly associated, highly prevalent in HD patients, associated with adverse
prognosis, increased morbidity and all-cause mortality.
The aim of our study is to evaluate the extent of vascular calcifications
using aortic calcium score and the association bethween calcium score,
cardiovascular risk factors and the severity of bone disease using heel
quantitative ultrasound.
Methods: We conducted a retrospective study which enrolled 90 consec-
utive non-diabetic patients receiving maintenance HD, 50.6% men, age
53.8±21.8 years, 31.5% of patients over 65y. The etiology ESRD: glomeru-
lar nephropathy 33.7%, ADPKD 20.5% and vascular nephropathy 19.1%.
None of the patients had diabetic nephropathy. The mean HD duration
was 4.32±3years and 34% of patients had >5years HD vintage. 73.5%
pts were hypertensive and 72% of them were controlled. 44% were treated
with statins, 89% with calcium based phosphate binders and 58% with
alfacalcidol.
Results: Mean calcium score was 4±4.8 (median value 2 [0-19]). No
vascular calcifications were found in 22% of patients. Mean T score was
-1.7±0.9, but 43% of patients had T scores below -2.5 and only 19%
had positive values. Mean estimated BMD was 0.4±0.14g/cm3 (0.17-0.99).
Patients with calcium scores >2 compared with those without aortic calci-
fications are older (61.5±12.8yrs vs 44.9±12.9yrs), have a longer history
of hypertension (11±9.7yrs vs 3.8±6.1yrs), are obese (20% vs 5%), had
a marked inflammatory syndrome (CRP >3mg/dl 73% vs 25%; serum
albumin <3.5mg/dl 80% vs 30%; ferritin >500ng/ml 56% vs 30% despite
lower doses of iron supplements). They also had more frequently aortic
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valve (52.2% vs 10.5%) and/or mitral valve calcifications (33.3% vs 5.3%),
carotid atherosclerotic plaques (89% vs 25%) particularly of heteroge-
neous echographic structure (37% vs 5%), with higher calcium content
(84.8% vs 15%) and higher intima–media thickness index (1.13±0.15 vs
0.9±0.15mm). There were no differences between the 2 groups regard-
ing HD vintage, calcium–phosphorus metabolism markers (serum calcium,
serum phosphate, CaP product and PTH) or lipid metabolism (cholesterol,
triglycerides, HDL and LDL cholesterol). The patients with vascular calcifi-
cation have significantly lower T scores (-2±0.9 vs -1.4±0.7) with a higher
percentage of patients in the lower than 2.5 range (57 vs 20%).
Conclusions: We can conclude that there is a strong relationship between
aortic calcium score and valvular calcifications or carotid atherosclerotic
plaques. Aortic calcium score is significantly associated with bone disease in
our group. Age, obesity, personal history of hypertension and inflammatory
syndrome are risk factors for vascular calcification. This simple aortic
calcification score seems to be a good marker of cardiovascular and bone
pathology in HD patients.
SaP278 VASCULAR CALCIFICATION IN INCIDENT DIALYSIS
PATIENTS
Mhairi K. Sigrist 1 , Pete Bungay 2, Maarten W. Taal 1, Chris W. McIntyre 1.
1Department of Renal Medicine, Derby City General Hospital, Derby,
United Kingdom; 2Department of Imaging, Derby City General Hospital
Introduction and Aims: Vascular calcification plays an important role in the
pathophysiology of cardiovascular disease in dialysis patients. The impact
of dialysis initiation on the progression of calcification has not previously
been described. The objective of this study was to prospectively investigate
the progression of vascular calcification in incident haemodialysis and
peritoneal dialysis patients.
Methods: 46 CKD stage 4 subjects entered this study. Patients were
studied at 12-month intervals. Vascular calcification was assessed using
multi-slice spiral CT scanning of a 5 cm standardised segment of superficial
femoral artery (SFA). Calcification scoring (CaSc) was undertaken using the
Agatston score. All medications were recorded and biochemical parameters
were time averaged over 12 months.
Results: After 24 months, 14 patients initiated PD, 12 initiated HD and 17
patients had not started dialysis (CKD 4) (2 died and 1 withdrew). Mean age
was comparable between the three groups (61±13, 57±15 and 62±13 years
respectively). Incident HD patients had significantly higher CaSc at baseline
than the other two groups (median CaSc 221 (IQR 2-524) in HD compared
to zero (IQR 0-108) in PD and CKD 4, P<0.01). Significant progressive
calcification was observed in all patients with a positive calcification score
at baseline, calcification increased from a median of 103 (IQR 5-367) to
253 (IQR 13-582). 4 patients initiated calcification from a baseline CaSc of
zero (3 CKD 4 patients and one PD patient). 19 patients who started with a
CaSc of zero had no change over 12 months (8 CKD 4, 8 PD and 2 HD).
Delta CaSc correlated with baseline CaSc (P<0.001) delta residual renal
function (P<0.01) and number of months on dialysis (P<0.01). Biochemical
variables associated with delta CaSc were osteoprotegerin (P<0.01) and
negatively with total cholesterol (P<0.01) and LDL cholesterol (P<0.05).
There were no significant differences in plasma phosphate, calcium or PTH
between patients. 18/46 patients used calcium-based phosphate binders at
baseline, 9 with and 9 without calcification.
Conclusions: Arterial calcification begins prior to the initiation of dialysis.
Pre-existing vascular calcification is the most important factor determining
its progression, however HD was associated with higher CaScs. Given its
associations with cardiovascular mortality, therapies targeting the progres-
sion of vascular calcification should begin prior to starting renal replacement
therapy.
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SaP279 COMPARISON BETWEEN HEMODIALYSIS PATIENTS
WITH DIFFERENT ARTERIAL CALCIFICATION STATUS
Saso Gelev 1, Goce Spasovski 1, Sonja Dzikova 1, Zoran Trajkovski 2,
Gjulsen Selim 1, Pavlina Dzekova 1, Vili Amitov 1, Aleksandar Sikole 1.
1Department of Nephrology; 2Institute of Radiology, Clinical Center,
Skopje, F.Y.R Macedonia
Introduction and Aims: The aims of this study were to evaluate presence
of different arterial calcifications, as well as to compare atherosclerotic
findings and risks between hemodialysis (HD) patients with different
arterial calcifications status.
Methods: In a cross-sectional study we examined 135 HD patients (84 men;
mean age 54.75±14.82 years; HD duration 101.87±64.89 months). Primar-
ily we evaluated the presence of arterial intima (AIC) and arterial media
calcifications (AMC) using plain radiography of the pelvis, and the presence
of atherosclerotic lesions using high resolution B-mode ultrasonography of
the common carotid arteries (CCA). Then we compared the potential clin-
ical, biochemical risk factors and different atherosclerotic findings among
the groups of the patients with different arterial calcifications.
Results: Our results showed frequent presence of AIC (n=61; 45.2%)
and AMC (n=46; 34.1%) in our HD patients. The patients (n=28; 20.7%)
without arterial calcifications and with AMC had high percentage of carotid
atherosclerotic plaques (28.6%/47.8%) and documented cardiovascular dis-
eases (46.4%/76.1%) respectively. Patients with AIC had significantly
(p<0.05) older age (59.4±11.8 vs 50.2±11.7, 47.1±10.9 years), smoking
habits (22.9 vs 8.7, 7.1%), diabetes (41.8 vs 19.6, 3.6%), male gender
(70.5 vs 35.7%), poorer dialysis adequacy (kt/v 1.23±0.17 vs 1.3±0.19,
1.32±0.2), lower body mass index (22.67±2.61 vs 25.44±6.47, 24.0±3.9
kg/m2), higher serum triglycerides (2.49±1.01 vs 1.88±0.86 mmol/L), lower
serum albumin (38.25±2.97 vs 39.51±2.92 g/L), increased CCA intima
media thickness (1.54±0.27 vs 1.42±0.29 mm), hypertensive nephropathy
(31.1%) as a cause of renal failure, CCA atherosclerotic plaques (80.3%),
calcified intimal plaques (59.1%), documented cardiovascular (85.2%),
cerebrovascular (36.1%) and peripheral arterial diseases (49.2%) in compar-
ison with other patients. Significantly (p<0.05) frequent presence of male
gender (67.4 vs 35.7%), diabetes (19.6 vs 3.6%) and internal diameter on
CCA (7.64±1.1 vs 7.07±0.95 mm) were found in patients with AMC in
comparison with patients without arterial calcifications. We did not find
statistically differences in other atherosclerotic (blood pressure, other serum
lipids, C-reactive protein) and in HD specific risks (doses of prescribed
calcium carbonate and vitamin D3, serum levels of phosphate, calcium
phosphate product, intact parathyroid hormone and duration of HD).
Conclusions: Arterial calcifications in HD patients are frequent. The
patients with AMC and without arterial calcifications have high percentage
of atherosclerotic lesions and complications. In our patients AIC were
associated with older age, smoking habits, diabetes, male gender, poorer
dialysis adequacy, lower body mass index, higher serum triglycerides, lower
serum albumin. AMC were associated with male gender and diabetes. In
our patients the role of HD specific risks in formation of different arterial
calcifications needs to be further elucidated in additional large scale study.
SaP280 AN UNUSUAL CAUSE OF PLEURAL EFFUSION IN A
HAEMODIALYSIS PATIENT
Antonella Serra, Patrizia Scotto, Stefano Murtas, Piergiorgio Bolasco.
U.O.Territoriale di Nefrologia e Dialisi, ASL 8 - Cagliari, Quartu S.E., Italy
Introduction and Aims: Pleural effusion is not usually the first sign of
constrictive pericarditis. The aim of this report was to highlight that
constrictive pericarditis should, however, always be considered as a possible
cause of pleural effusion in haemodialysis patients, as the prognosis depends
on an early diagnosis.
Methods: We present a case of constrictive pericarditis occurring in a
66-year-old man on haemodialysis. Previously the patient had received
a cadaveric renal transplantation, but after 14 years, haemodialysis was
resumed on account of chronic allograft nephropathy. A few months
later, bilateral pleural effusion was diagnosed. To establish the cause of
the pleural effusion, several assessments were carried out. They included
